Heterocyclic POLQ inhibitors

Heterocyclic compounds targeting POLQ provide a solution for treating HRD tumors and overcoming therapy resistance by inhibiting POLQ activity, enhancing sensitivity to DNA-damaging agents and improving bioavailability.

WO2026238607A1PCT designated stage Publication Date: 2026-11-19MERCK PATENT GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063544
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-11
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

There is a need for selective POLQ inhibitors that demonstrate good bioavailability and are suitable for dosing, particularly for the treatment of HRD tumors and overcoming therapy resistance associated with BRCA mutations.

Method used

Development of heterocyclic compounds of Formulas I and II that inhibit POLQ, which are designed to target HRD tumors and enhance sensitivity to DNA-damaging agents.

Benefits of technology

The compounds effectively inhibit POLQ activity, offering potential therapeutic benefits in treating HRD tumors and overcoming resistance to PARP inhibitors, while being suitable for dosing and demonstrating good bioavailability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026063544_19112026_PF_FP_ABST
    Figure EP2026063544_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The invention provides heterocyclic compounds of the Formulas I and II that are inhibitors of the polymerase, DNA polymerase theta (PolΘ or POLQ) and are particularly useful in the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

P25-212-PRI-US01HETEROCYCLIC POLQ INHIBITORSFIELD OF THE INVENTION

[0001] The invention provides heterocyclic compounds of the Formulas I and II that are inhibitors of the polymerase, DNA polymerase theta (PolΘ or POLQ) and are particularly useful in the treatment of cancer.BACKGROUND OF THE INVENTION

[0002] DNA polymerase theta (Pol0) is a specialized polymerase encoded in the human genome by the POLQ gene and hence it is also simply known as POLQ. It belongs to the A family, a group of DNA polymerases regarded as error prone due to their lack of proofreading activity. It is the only human DNA polymerase that also contains an active DNA helicase domain (Loeb, L. A, and Monnat, R. J., Jr.(2008). DNA Polymerases and Human Disease. Nat Rev Genet 9, 594-604. Ramsden et al. (2022) Mechanism, Cellular Functions and Cancer Roles of Polymerase-Theta-Mediated DNA End Joining. Nature Reviews Molecular Cell Biology, 23, 125-140). POLQ has been involved in genome maintenance processes through its roles in translesion synthesis (TLS), a DNA-damage tolerance mechanism, and alternative DNA-end joining (alt-EJ), a DNA repair mechanism involved in the resolution of DNA double-strand breaks (DSBs) (Ramsden etal. (2022) Mechanism, Cellular Functions and Cancer Roles of Polymerase-Theta-Mediated DNA End Joining.Nature Reviews Molecular Cell Biology, 23, 125-140; Yoon, J. -H., McArthur, M. J., Park, J., Basu, D., Wakamiya, M., Prakash, L., and Prakash, S. (2019). Error-Prone Replication through UV Lesions by DNA Polymerase 0 Protects against Skin Cancers. Cell 176, 1295-1309).

[0003] DNA DSBs are the most cytotoxic lesion faced by cells and several DNA-damage signaling and repair mechanisms have evolved to deal with them. In human cells, DSB repair is mostly performed by the non-homologous end joining (NHEJ) and homologous recombination repair (HRR) pathways, with a third pathway, named alt-EJ, generally regarded as a less frequently used option. The first steps of the HRR and alt-EJ pathways are shared, where the ends of the DNA DSB will beP25-212-PRI-US01processed (resected) to generate regions of single-stranded DNA (ssDNA). While during HRR resection is relatively extensive, it is kept to shorter stretches during alt-EJ through a mechanism that remained elusive. In addition, alt-EJ has been linked to the use of sequence microhomologies (2-6 base pairs) surrounding the DSB site for repair by direct annealing, processing of the DNA flaps and ligation, which explains its error-prone nature. As such, alt-EJ is also referred to as microhomology-mediated end joining (MMEJ) (Ciccia and Elledge, (2010) The DNA Damage Response: Making it Safe to Play with Knives. Mol Cell, 43, 179-204).

[0004] HRR is a form of DNA repair that, once a DSB has occurred on a chromosome's chromatid, uses the sister chromatid as template for repair. As such, HRR is regarded as error-free and can only take place once a sister chromatid is available, namely during the DNA replication (synthesis) phase (S phase) and gap phase 2 (G2 phase) of the cell cycle. HRR deficiency (HRD) is well described in tumors and is genetically associated with mutations in the breast cancer susceptibility genes BRCAJ and BRCA2 (BRCA genes), among others (Pellegrino et al., 2019 Controversies in Oncology: are Genomic Tests Quantifying Homologous Recombination Repair Deficiency (HRD) Useful for Treatment Decision Making? ESMO Open.). HRD is also associated with increasing levels of genomic instability, highlighted by the presence of specific mutational signatures involving single-base substitutions (SBS), insertions-deletions (INDEL) and rearrangements (Nik-Zainal et al., 2016, Landscape of Somatic Mutations in 560 Breast Cancer Whole-Genome Sequences, Nature, 534, 47-54). Interestingly, the SBS signature associated with HRD (SBS3), is also associated with an INDEL signature (ID6) that is characterized by extensive microhomology usage at the break point (Alexandrov et al., 2020 The Repertoire of Mutational Signatures in Human Cancer. Nature 578, 94-101.), suggesting that MMEJ could be an important DNA repair pathway in the absence of HRR. In agreement with this, signatures of MMEJ-mediated repair events have been identified in secondary (reversion) mutations restoring the open-reading frame of BRCA and other HRR-related genes in tumors from patients progressing on treatment, strongly suggesting that these reversion events are mediated by MMEJ repair and driving therapy resistance in these clinical cases (Pettitt et al., 2020 Clinical BRCAI / 2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance. Cancer Discov. 10(10): 1475-1488; TobalinaP25-212-PRI-US01et al., 2021, A Meta-Analysis of Reversion Mutations in BRCA Genes Identifies Signatures of DNA End-Joining Repair Mechanism Driving Therapy Resistance. Annals of Oncology, 32, 103-112).

[0005] Recently, POLQ has been involved in MMEJ repair while not playing a significant role in HRR, making it the only MMEJ-specific protein known to date (Wyatt et al., 2016; Yousefzadeh et al., 2014. Essential Roles for Polymerase theta-Mediated End Joining in the Repair of Chromosome Breaks. Mol Cell 63, 662-673). Interestingly, reports have highlighted a synthetic lethal genetic dependency between inactivating mutations in genes involved in HRR (BRCAJ, BRCA2, FANCD2, ATM) and lack of POLQ activity (Ceccaldi et al., 2015 Homologous-recombination-deficient tumors are dependent on Poltheta-mediated repair. Nature 518, 258-262.; Mateos-Gomez et al., 2015 Mammalian Polymerase Theta Promotes Alternative NHEJ and Suppresses Recombination. Nature 518, 254-257; Shima et al., 2004, The Mouse Genomic Instability Mutation Chaos 1 is an Allele of POLQ that Exhibits Genetic Interaction with Atm. Mol Cell Biol 24, 10381- 10389), being that activity either polymerase or helicase (Mateos-Gomez et al., 2017 The Helicase Domain of Pol [theta] Counteracts RPA to Promote alt-NHEJ. Nat Struct Mol Biol 24, 1116-1123). As such, there is an increasing interest in developing POLQ inhibitors for the treatment of HRD tumors, both as single agents or in combination with poly(ADP-ribose) polymerase (PARP) inhibitors (Zatreanu et al., 2021 PolΘ inhibitors elicit BRCA- gene synthetic lethality and target PARP inhibitor resistance. Nature Communications 12, 3636.; Zhou et al., 2021, A First-in-Class Polymerase Theta Inhibitor Selectively Targets Homologous-Recombination-Deficient Tumors. Nature Cancer 2, 598-610).Importantly, it has also been shown that POLQ-deficient cells are sensitive to DNA damaging agents including ionizing radiation (Higgins et al., 2010, A Small interfering RNA screen of genes involved in DNA repair identifies tumor-specific Radio Sensitization by POLQ Knockdown. Cancer Res 70, 2984-2993.;Yousefzadeh et al., 2014, Mechanism of Suppression of Chromosomal Instability by DNA Polymerase POLQ. PLoS Genet 10, el 004654.), which could open the possibility of combinations of POLQ inhibitors with chemo- or radiotherapy (Higgins and Boulton, 2018, Beyond PARP-POLΘ as an Anticancer Target.Science 359, 1217-1218).P25-212-PRI-US01

[0006] Accordingly, there is a need for POLQ inhibitors that are selective, demonstrate good bioavailability and are suitable for dosing.SUMMARY OF THE INVENTION

[0007] One embodiment disclosed herein provides a compound of Formula I or II or pharmaceutically acceptable salt thereof, or stereoisomer thereof

[0008] wherein:

[0009] R1is independently selected for each occurrence from the group consisting of C1-C6 alkyl, C1-C6haloalkyl, -O-C1-C6 alkyl and hydrogen;

[0010] XisN or CR2;

[0011] R2is selected from the group consisting of halogen, C1-C6alkyl, C1-C6haloalkyl, -O-C1-C6alkyl and hydrogen;

[0012] A is selected from the group consisting of optionally substituted aromatic, optionally substituted heteroaromatic, optionally substituted Cs-Cs cycloalkyl and optionally substituted C2-C8 heteroalkyl or a diastereomer or enantiomer thereof or a pharmaceutically acceptable salt thereof.

[0013] In another embodiment there is provided compounds of Formula I and II wherein A is selected from the group consisting ofP25-212-PRI-US01

[0014] R3is selected independently for each occurrence from the group consisting of hydrogen, halogen, C1-C8alkyl, C1-C6haloalkyl, -NR4R5,

[0015] R4and R5are each independently selected from the group consisting ofhydrogen,

[0016] R6is selected from the group consisting of C1-C6haloalkyl, C1-C8alkyl and Ci-Cs alkenyl;

[0017] R7is selected from hydrogen and C1-C8alkyl;

[0018] R8is independently selected from the group consisting of hydrogen, C1-C6

[0019] R9is selected from the group consisting of C1-C6haloalkyl, C1-C8alkyl andCi-Cs alkenyl;P25-212-PRI-US01

[0020] R10and R11are each independently selected from hydrogen and C1-C6 alkyl or maybe taken together to form a 3-8 member carbocyclic ring optionally interrupted by 1-3 heteroatoms chosen from -O- and -NR12-;

[0021] R12is selected from hydrogen and C1-C6 alkyl;

[0022] n is selected from 0, 1, 2 and 3;

[0023] m is selected from 0, 1, 2 and 3 and

[0024] p is selected from 1, 2, 3 and 4.

[0025] In another embodiment there is provided compounds of Formula I and II wherein R1is selected independently for each occurrence from the group consisting of hydrogen and halogen. Preferably, R1is selected independently for each occurrence from the group consisting of -F and hydrogen.

[0026] In another embodiment there is provided compounds of Formula I and II wherein X is N.

[0027] In another embodiment there is provided compounds of Formula I and II wherein X is CR2.

[0028] In another embodiment there is provided compounds of Formula I and II wherein R2is selected from the group consisting of hydrogen and halogen. Preferably R2is hydrogen. Preferably R2is -F.

[0029] In another embodiment there is provided compounds of Formula I and II wherein A is

[0030] In another embodiment there is provided compounds of Formula I and II wherein R3is independently selected for each occurrence from the group consisting of hydrogen, -CH3 and -NR4R5wherein R4and R5are each independently selectedfrom the group consisting of hydrogen,P25-212-PRI-US01

[0031] and R6is selected from the group consisting of C1-C6 haloalkyl, C1-C8alkyl and Ci-Cs alkenyl.

[0032] In another embodiment there is provided compounds of Formula I and II wherein -NR4R5is selected from the group consisting of

[0033] wherein R13and R14are independently selected from hydrogen, halogen and C1-C2 alkyl. Preferably R13is -CH3 and R14is -Cl. Preferably R13is -F and R14is -Cl.

[0034] In another embodiment there is provided compounds of Formula I and II wherein R3is selected from the group consisting of hydrogen, -CH3,P25-212-PRI-US01

[0036] and R9is selected from the group consisting of C1-C6 haloalkyl, C1-C8alkyl and Ci-Cs alkenyl.

[0037] In another embodiment there is provided compounds of Formula I and II wherein R8is selected fromwhereinR15is a halogen or C1-C2 alkyl. Preferably R15is chloro.

[0038] In another embodiment there is provided compounds of Formula I and II wherein A is selected from the group consisting of

[0039] wherein R3is independently selected for each occurrence from the group consisting of hydrogen, halogen, C1-C8alkyl and C1-C6 haloalkyl; and R4is hydrogen or -CH3.

[0040] Preferably R3is selected from the group consisting of hydrogen, -CF3 and -CH3.

[0041] In another embodiment there is provided compounds of Formula I and II wherein A is selected from the group consisting of

[0042] In another embodiment a compound or a pharmaceutically acceptable salt thereof selected from the group consisting ofP25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01

[0043] Rac meaning racemic mixture.In another embodiment a method of treating cancer which comprises administering to a patient in need thereof, a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to Formulas I or II is provided. Preferably the cancer is a solid cancer.P25-212-PRI-US01Preferably the cancer is breast, ovarian, pancreatic or prostate.Preferably the cancer comprises a BRCA1 and / or BRCA2 mutation.

[0044] Every combination of variables, substituents, embodiments and the compounds that result from these combinations, is deemed specifically and individually disclosed, as such depiction is for convenience of space only and not intended to describe only a genus or even a subgenus of compounds.

[0045] A compound of the present invention provided herein or its pharmaceutically acceptable salt and / or its pharmaceutically acceptable composition can be used to treat a disorder which is mediated by POLQ. In some embodiments a method to treat a patient with a disorder mediated by POLQ is provided that includes administering an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, to the patient, typically a human, optionally in a pharmaceutically acceptable composition.

[0046] A compound of the present invention may be used to treat a POLQ-mediated disorder such as colon cancer; rectal cancer; endometrial cancer; lung cancer, including non-small cell lung cancer; pancreatic cancer; thyroid cancer; astrocytoma; esophageal cancer; cervical cancer; small intestinal cancer; ovarian cancer; gastric cancer; breast cancer; bladder cancer; or kidney cancer.

[0047] In certain embodiments, a method of treatment is provided comprising administering an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof to a human patient in need thereof, optionally in a pharmaceutically acceptable carrier. For example, in certain embodiments, a compound of the present invention is administered to a human to treat a cancer.

[0048] Another aspect of the present invention provides a compound as described herein, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, or solvate thereof, or a pharmaceutical composition, for use in the manufacture of a medicament for treating a disorder mediated by POLQ.

[0049] Another aspect of the present invention provides a compound as described herein, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, or solvate thereof, or its pharmaceutical composition, for use in the manufacture of a medicament for treating a disease mediated by POLQ.

[0050] In certain embodiments, a selected compound as described herein is useful to treat a disorder comprising an abnormal cellular proliferation, such as a tumor or cancer, wherein POLQ is an oncogenic protein or a signaling mediator of theP25-212-PRI-US01abnormal cellular proliferative pathway and its degradation decreases abnormal cell growth.

[0051] In certain embodiments, a compound of the present invention, or its pharmaceutically acceptable salt thereof, has at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e., enriched.

[0052] In certain embodiments, a compound of the present invention, or its pharmaceutically acceptable salt thereof, includes a deuterium atom or multiple deuterium atoms.

[0053] Other features and advantages of the present application will be apparent from the following detailed description.

[0054] The present invention thus includes at least the following features:

[0055] A compound of the present invention, or a pharmaceutically acceptable salt or isotopic derivative (including a deuterated derivative) thereof;

[0056] A method for treating a POLQ mediated disorder, such as an abnormal cellular proliferation, including cancer, comprising administering an effective amount of a compound of the present invention, or pharmaceutically acceptable salt thereof, as described herein, to a patient in need thereof;

[0057] A compound of the present invention, or a pharmaceutically acceptable salt, or isotopic derivative (including a deuterated derivative) thereof for use in the treatment of a disorder that is mediated by POLQ, for example an abnormal cellular proliferation such as a tumor or cancer;

[0058] Use of a compound of the present invention, or a pharmaceutically acceptable salt thereof, in an effective amount in the treatment of a patient in need thereof, with a POLQ mediated disorder, for example an abnormal cellular proliferation such as a tumor or cancer;

[0059] Use of a compound of the present invention, or a pharmaceutically acceptable salt or isotopic derivative (including a deuterated derivative) thereof in the manufacture of a medicament for the treatment of a POLQ mediated disorder, for example an abnormal cellular proliferation such as a tumor or cancer;

[0060] A method for treating a mutant POLQ mediated disorder, such as an abnormal cellular proliferation, including cancer, comprising administering an effective amount of a compound of the present invention, or pharmaceutically acceptable salt thereof, as described herein, to a patient in need thereof;P25-212-PRI-US01

[0061] A pharmaceutical composition comprising an effective patient-treating amount of a compound of the present invention, or a pharmaceutically acceptable salt, isotopic derivative thereof; and optionally a pharmaceutically acceptable carrier or diluent;

[0062] A compound the present invention, as described herein as a mixture of enantiomers or diastereomers (as relevant), including as a racemate;

[0063] A compound of the present invention, as described herein in enantiomerically or diastereomerically (as relevant) enriched form, including an isolated enantiomer or diastereomer (i.e., about greater than 85, 90, 95, 97, or 99% pure);

[0064] A process for the preparation of therapeutic products that contain an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, as described herein;

[0065] A compound of Formula I or II, as described herein, or a pharmaceutically acceptable salt or isotopic derivative (including a deuterated derivative) thereof;

[0066] A compound of Formula I or II, as described herein, or a pharmaceutically acceptable salt or isotopic derivative (including a deuterated derivative) thereof; and

[0067] A method for treating a POLQ mediated disorder, such as an abnormal cellular proliferation, including cancer, comprising administering an effective amount of a compound of Formula I or II, or pharmaceutically acceptable salt thereof, as described herein, to a patient in need thereof;DETAILED DESCRIPTION OF THE INVENTION

[0068] Compounds and their uses and manufacture are provided of Formula I or II or pharmaceutically acceptable salt thereof, or stereoisomer thereofP25-212-PRI-US01

[0069] wherein:R1is independently selected for each occurrence from the group consisting of C1-C6alkyl, C1-C6haloalkyl, -O-C1-C6alkyl and hydrogen;X is N or CR2;R2is selected from the group consisting of halogen, C1-C6alkyl, C1-C6haloalkyl, -O-C1-C6alkyl and hydrogen;A is selected from the group consisting of optionally substituted aromatic, optionally substituted heteroaromatic, optionally substituted C3-C8 cycloalkyl and optionally substituted C2-C8 heteroalkyl.

[0070] In certain embodiments one stereocenter is in the R configuration and any others present are either enantiomerically enriched or substantially pure. In certain embodiments one stereocenter is in the S configuration and any others present are either enantiomerically enriched or substantially pure.

[0071] In certain embodiments one stereocenter is in the R configuration and any others present are without regard to stereochemistry, enantiomerically enriched or substantially pure. In certain embodiments one stereocenter is in the S configuration and any others present are without regard to stereochemistry, enantiomerically enriched or substantially pure.P25-212-PRI-US01

[0072] Additional features, advantages, and embodiments of the disclosed subject matter may be set forth or apparent from consideration of the following detailed description and claims. Moreover, it is to be understood that both the foregoing summary and the following detailed description are exemplary and are intended to provide further explanation without limiting the scope of the claims. All cited references are incorporated by reference in their entirety.DEFINITIONS

[0073] Compounds are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this invention belongs.

[0074] The compounds of the present invention may be in the form of a racemate, enantiomer, mixture of enantiomers, diastereomer, mixture of diastereomers, tautomer, A-oxide, isomer; such as rotamer, as if each is specifically described unless specifically excluded by context.

[0075] The terms “a” and “an” do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item(s). The term “or” means “and / or”. Recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The endpoints of all ranges are included within the range and independently combinable. All methods described herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of examples, or exemplary language (e.g., “such as”), is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed.

[0076] The present invention includes a compound of the present invention with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e., enriched. Isotopes are atoms having the same atomic number but different mass numbers, i.e., the same number of protons but a different number of neutrons.

[0077] Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous,P25-212-PRI-US01fluorine, chlorine and iodine such as2H,3H,11C,13C,14C,15N,17O,18O,18F,31P,32P,35S,36C1, and125I respectively. In certain embodiments, isotopically labelled compounds can be used in metabolic studies (with, for example14C), reaction kinetic studies (with, for example2H or3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an18F labeled compound may be particularly desirable for PET or SPECT studies. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

[0078] Isotopic substitutions, for example deuterium substitutions, can be partial or complete. Partial deuterium substitution means that at least one hydrogen is substituted with deuterium. In certain embodiments, the isotope is 90, 95 or 99% or more enriched in an isotope at any location of interest. In certain embodiments, deuterium is 90, 95 or 99% enriched at a desired location.

[0079] In certain embodiments, the substitution of a hydrogen atom for a deuterium atom can be provided in any compound of the present invention. In certain embodiments, the substitution of a hydrogen atom for a deuterium atom occurs within one or more groups selected from any of R’s or variables described herein. For example, when any of the groups are, or contain for example through substitution, methyl, ethyl, or methoxy, the alkyl residue may be deuterated (in non-limiting embodiments, CDH2, CD2H, CD3, CH2CD3, CD2CD3, CHDCH2D, CH2CD3, CHDCHD2, OCDH2, OCD2H, or OCD3etc ). In certain other embodiments, when two substituents are combined to form a cycle, the unsubstituted carbons may be deuterated.

[0080] In certain embodiments, a compound of the present invention is isotopically labeled. In certain embodiments, at least one R group is isotopically labeled with 1, 2, or more isotopes as allowed by valence. In certain embodiments, the isotopic label is deuterium. In certain embodiments, at least one deuterium is placed on an atom that has a bond which is broken during metabolism of the compound in vivo, or is one, two or three atoms remote form the metabolized bond (e.g., which may be referred to asP25-212-PRI-US01an α, β or γ, or primary, secondary or tertiary isotope effect). In other embodiments, the isotopic label is13C. In other embodiments, the isotopic label is18F.

[0081] The compound of the present invention may form a solvate with a solvent (including water). Therefore, in certain non-limiting embodiments, the invention includes a solvated form of the compound. The term “solvate” refers to a molecular complex of a compound of the present invention (including a salt thereof) with one or more solvent molecules. Non-limiting examples of solvents are water, ethanol, isopropanol, dimethyl sulfoxide, acetone and other common organic solvents. The term “hydrate” refers to a molecular complex comprising a compound of the invention and water. Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent may be isotopically substituted, e.g., D2O, acetone-6, DMSO-6(dimethyl sulfoxide). A solvate can be in a liquid or solid form.

[0082] A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -(C=O)NH2 is attached through carbon of the carbonyl (C=O) group.

[0083] “Alkyl” is a branched or straight chain saturated aliphatic hydrocarbon group. Unless denoted otherwise, “alkyl” is typically a C1-C8alkyl. In certain non-limiting embodiments, the alkyl group contains from 1 to 12 carbon atoms, more generally from 1 to 6 carbon atoms or from 1 to 4 carbon atoms. In certain non-limiting embodiments, the alkyl contains from 1 to 8 carbon atoms. In certain embodiments, the alkyl is C1-C2, C1-C3, C1-C4, C1-C5, or C1-C6. The specified ranges as used herein indicate an alkyl group having each member of the range described as an independent species. For example, the term C1-C6 alkyl as used herein indicates a straight or branched alkyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each of these is described as an independent species and therefore each subset is considered separately disclosed. For example, the term C1-C4 alkyl as used herein indicates a straight or branched alkyl group having from 1, 2, 3, or 4 carbon atoms and is intended to mean that each of these is described as an independent species. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, / -butyl, n-pentyl, isopentyl, tert-pentyl, neopentyl, n-hexyl, 2-methylpentane, 3 -methylpentane, 2,2-dimethylbutane, and 2,3-dimethylbutane. The term “alkyl” also encompasses cycloalkyl or carbocyclic groups. For example, when a term is used that includes “alk” then “cycloalkyl” or “carbocyclic” can be considered part of the definition, unless unambiguouslyP25-212-PRI-US01excluded by the context. For example, and without limitation, the terms alkyl, alkoxy, haloalkyl, etc., can all be considered to include the cyclic forms of alkyl, unless unambiguously excluded by context.

[0084] Non-limiting examples of “cycloalkyl” include dihydro-indene and tetrahydronaphthalene wherein the point of attachment for each group is on the cycloalkyl ring.

[0085] For example:group.

[0086] However,group.

[0087] The term “alkoxy” denotes a group of the formula -O-alkyl. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, and tert-butoxy.

[0088] The term “cycloalkoxy” denotes a group of the formula -O-cycloalkyl.Examples of cycloalkoxy group include cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, and cyclooctyloxy.

[0089] “Alkenyl” is a linear or branched aliphatic hydrocarbon groups having one or more carbon-carbon double bonds that may occur at a stable point along the chain. Unless denoted otherwise, “alkenyl” is typically a C2-C8 alkenyl. The specified ranges as used herein indicate an alkenyl group having each member of the range described as an independent species, as described above for the alkyl moiety. In certain nonlimiting embodiments, the alkenyl contains from 2 to 12 carbon atoms, from 2 to 6 carbon atoms or from 2 to 4 carbon atoms. In certain embodiments, the alkenyl is C2, C2-C3, C2-C4, C2-C5, or C2-Cealkenyl. Examples of alkenyl radicals include, but are not limited to ethenyl, propenyl, allyl, propenyl, butenyl and 4-methylbutenyl. The term “alkenyl” also embodies “cis” and “trans” alkenyl geometry, or alternatively, “E” and “Z” alkenyl geometry. The term “Alkenyl” also encompasses cycloalkyl or cycloalkyl groups possessing at least one point of unsaturation.

[0090] “Alkynyl” is a branched or straight chain aliphatic hydrocarbon group having one or more carbon-carbon triple bonds that may occur at any stable point along the chain. Unless denoted otherwise, “alkynyl” is typically a C2-C8 alkynyl. The specified ranges as used herein indicate an alkynyl group having each member of the range described as an independent species, as described above for the alkyl moiety. InP25-212-PRI-US01certain non-limiting embodiments, the alkynyl contains from 2 to 12 carbon atoms, more generally from 2 to 6 carbon atoms or from 2 to 4 carbon atoms. In certain embodiments, the alkynyl is C2, C2-C3, C2-C4, C2-C5, or C2-Cealkynyl. Examples of alkynyl include, but are not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1 -pentynyl, 2-pentynyl, 3 -pentynyl, 4-pentynyl, 1 -hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl. The term “Alkynyl” also encompasses cycloalkyl or cycloalkyl groups possessing at least one triple bond.

[0091] “Alkylene” is a bivalent saturated hydrocarbon. Alkylenes, for example, can be a 1, 2, 3, 4, 5, 6, 7 to 8 carbon moiety, 1 to 6-carbon moiety, or an indicated number of carbon atoms, for example Ci-C2alkylene, Ci-Csalkylene, Ci-C4alkylene, Ci-Csalkylene, or C1-C6alkylene.

[0092] “Alkenylene” is a bivalent hydrocarbon having at least one carbon-carbon double bond. Alkenylenes, for example, can be a 2 to 8 carbon moiety, 2 to 6-carbon moiety, or an indicated number of carbon atoms, for example C2-C4alkenylene.

[0093] “Alkynylene” is a bivalent hydrocarbon having at least one carbon-carbon triple bond. Alkynylenes, for example, can be a 2 to 8 carbon moiety, a 2 to 6-carbon moiety, or an indicated number of carbon atoms, for example C2-C4alkynylene.

[0094] The term “cyano” denotes a -C=N group.

[0095] The term “hydroxy” denotes a -OH group.

[0096] “Halo” and “Halogen” refers independently to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). Unless otherwise indicated “halo” or “halogen” typically refers to fluorine (F), chlorine (Cl), and bromine (Br). In certain embodiments “halo” or “halogen” is fluorine (F).

[0097] “Haloalkyl” is a branched or straight-chain alkyl groups substituted with 1 or more halo atoms described above, up to the maximum allowable number of halogen atoms. Unless denoted otherwise, “haloalkyl” is typically a C1-C4 haloalkyl.Examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, di chloroethyl and di chloropropyl. “Perhaloalkyl” means an alkyl group having all hydrogen atoms replaced with halogen atoms. Examples include, but are not limited to, trifluoromethyl and pentafluoroethyl.

[0098] “Chain” indicates a linear chain to which all other chains, long or short or both, may be regarded as being pendant. Where two or more chains could equally beP25-212-PRI-US01considered to be the main chain, “chain” refers to the one which leads to the simplest representation of the molecule.

[0099] “Haloalkoxy” indicates a haloalkyl group as described herein attached through an oxygen bridge (oxygen of an alcohol radical).

[0100] “Heterocycloalkyl” is an alkyl group as described herein substituted with a heterocyclo group as described herein.

[0101] “Arylalkyl” is an alkyl group as described herein substituted with an aryl group as described herein.

[0102] Non-limiting examples of “arylalkyl” include:

[0104] In certain embodiments, the “arylalkyl” refers to a 2-carbon alkyl group substituted with an aryl group.

[0105] Non-limiting examples of “arylalkyl” also include:

[0106] In certain embodiments, the “arylalkyl” refers to a 3 -carbon alkyl group substituted with an aryl group.

[0107] “Heteroarylalkyl” is an alkyl group as described herein substituted with a heteroaryl group as described herein.

[0108] As used herein, “aryl” refers to a radical of a monocyclic or polycyclic (e.g, bicyclic or tricyclic) 4n+2 aromatic ring system (e.g, having 6, 10, or 14 π electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“Ce-14 aryl”). In some embodiments, an aryl group has 6 ring carbon atoms (“Ce aryl”; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms (“Cio aryl”; e.g., naphthyl such as 1-naphthyl and 2-P25-212-PRI-US01naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms (“Cuaryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocycle groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. The one or more fused carbocyclyl or heterocycle groups can be 4 to 7 or 5 to 7-membered saturated or partially unsaturated carbocyclyl or heterocycle groups that optionally contain 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, phosphorus, sulfur, silicon and boron, to form, for example, a 3,4-methylenedioxyphenyl group.

[0109] In certain embodiments, “aryl” is a 6-carbon aromatic group fused to a heterocycle wherein the point of attachment is the aryl ring. Non-limiting examples of “aryl” include indoline, tetrahydroquinoline, tetrahydroisoquinoline, and dihydrobenzofuran wherein the point of attachment for each group is on the aromatic ring.

[0110] For example,group.

[0111] However, Co is a“heterocycle” group.

[0112] In certain embodiments, “aryl” is a 6-carbon aromatic group fused to a cycloalkyl wherein the point of attachment is the aryl ring. Non-limiting examples of “aryl” include dihydro-indene and tetrahydronaphthalene wherein the point of attachment for each group is on the aromatic ring.

[0113] For example, oCO ' is an “aryl” group.

[0114] However, O > is a “cycloalkyl” group.

[0115] The term “heterocyclyl”, “heterocycle”, and “heterocyclo” includes saturated, and partially saturated heteroatom-containing ring radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Heterocyclic rings comprise monocyclic 3, 4, 5, 6, 7, 8, 9, or 10 membered rings, as well as 5, 6, 7, 8, 9, 10, 11, 12,P25-212-PRI-US0113, 14, 15, or 16 membered bicyclic ring systems (which can include bridged fused and spiro-fused bicyclic ring systems). It does not include rings containing -O-O-, -O-S- or -S-S- portions. Examples of saturated heterocyclo groups include saturated 3, 4, 5, or 6-membered heteromonocyclic groups containing 1, 2, 3, or 4 nitrogen atoms [e.g., pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, piperazinyl]; saturated 3, 4, 5, or 6-membered heteromonocyclic group containing 1 or 2 oxygen atoms and 1, 2, or 3 nitrogen atoms [e.g., morpholinyl]; saturated 3, 4, 5, or 6-membered heteromonocyclic group containing 1 or 2 sulfur atoms and 1, 2, or 3 nitrogen atoms [e.g., thiazolidinyl]. Examples of partially saturated heterocycle radicals include, but are not limited to, dihydrothienyl, dihydropyranyl, dihydrofuryl, and dihydrothiazolyl. Examples of partially saturated and saturated heterocyclo groups include, but are not limited to, pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, pyrazolidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, thiazolidinyl, dihydrothienyl, 2,3-dihydro-benzo[l,4]dioxanyl, indolinyl, isoindolinyl, dihydrobenzothienyl, dihydrobenzofuryl, isochromanyl, chromanyl, 1,2-dihydroquinolyl, 1, 2,3,4-tetrahydro-isoquinolyl, 1,2,3,4-tetrahydro-quinolyl, 2,3,4,4a,9,9a-hexahydro-1-3-aza-fluorenyl, 5,6,7-trihydro-l,2,4-triazolo[3,4-a]isoquinolyl, 3,4-dihydro-2-benzo[1,4]oxazinyl, benzo[l,4]dioxanyl, 2,3-dihydro-lH-lX’-benzo[ ]isothiazol-6-yl, dihydropyranyl, dihydrofuryl, isoquinolin- l(2H)-onyl, benzo[d]oxazol-2(3H)-onyl, l,3-dihydro-2J / -benzo[d]midazol-2-onyl, benzo[d]thiazole-2(3H)-onyl, 1,2-dihydro-3-pyrazol-3-onyl, 2(1)-pyridinonyl, 2-piperazinonyl, indolinyl, and dihydrothiazolyl.

[0116] The term “heterocyclyl”, “heterocycle”, and “heterocyclo” groups also include moieties where heterocycle radicals are fused / condensed with aryl or heteroaryl radicals: such as unsaturated condensed heterocycle group containing 1, 2, 3, 4, or 5 nitrogen atoms, for example, indoline, isoindoline, unsaturated condensed heterocycle group containing 1 or 2 oxygen atoms and 1, 2, or 3 nitrogen atoms, unsaturated condensed heterocycle group containing 1 or 2 sulfur atoms and 1, 2, or 3 nitrogen atoms, and saturated, partially unsaturated and unsaturated condensed heterocycle group containing 1 or 2 oxygen or sulfur atoms.

[0117] Additional non-limiting examples of “heterocycle” include indoline, tetrahydroquinoline, tetrahydroisoquinoline, and dihydrobenzofuran wherein the point of attachment for each group is on the heterocycle ring.P25-212-PRI-US01

[0118] For example,group.

[0119] However,group.

[0120] The term “heteroaryl” denotes a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic array) and 1, 2, 3, 4, 5, or 6, heteroatoms independently selected from O, N, and S, wherein the ring nitrogen and sulfur atom(s) are optionally oxidized, and nitrogen atom(s) are optionally quarternized. Examples include, but are not limited to, unsaturated 5- to 6-membered heteromonocyclyl groups containing 1, 2, 3, or 4 nitrogen atoms, such as pyrrolyl, imidazolyl, pyrazolyl, 2-pyridyl, 3 -pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl [e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl]; unsaturated 5- or 6-membered heteromonocyclic groups containing an oxygen atom, for example, pyranyl, 2 -furyl, 3-furyl, etc.; unsaturated 5- or 6-membered heteromonocyclic groups containing a sulfur atom, for example, 2-thienyl, 3-thienyl, etc.; unsaturated 5- or 6-membered heteromonocyclic groups containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl]; unsaturated 5 or 6-membered heteromonocyclic groups containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g.,1.2.4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl], Additional examples include 8-, 9-, or 10-membered heteroaryl bicyclic groups such as indazolyl, indolyl, imidazo[l,5-a]pyridinyl, benzimidazolyl, 4(3J7)-quinazolinonyl, quinolinyl, isoquinolinyl, isoindolyl, thi enothienyl, indolizinyl, benzofuranyl, isobenzofuranyl, benzothienyl, isobenzothienyl, benzoxazolyl, benzothiazolyl, purinyl, coumarinyl, cinnolinyl, and triazol opyridinyl.

[0121] The term “bicycle” refers to a ring system wherein two rings are fused together and each ring is independently selected from carbocycle, heterocycle, aryl, and heteroaryl. Bicyclic ring systems also include spiro-fused bicyclic ring systems. Non-limiting examples of bicycle groups include:P25-212-PRI-US01

[0122] When the term “bicycle” is used in the context of a bivalent residue such as Linker the attachment points can be on separate rings or on the same ring. In certain embodiments, both attachment points are on the same ring. In certain embodiments, both attachment points are on different rings. Non-limiting examples of bivalent bicycle groups include:

[0123] “Aliphatic” refers to a saturated or unsaturated, straight, branched, or cyclic hydrocarbon that is not aromatic. “Aliphatic” is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties, and thus incorporates each of these definitions. In certain embodiments, “aliphatic” is used to indicate those aliphatic groups having 1-20 carbon atoms. The aliphatic chain can be, for example, mono-unsaturated, di-unsaturated, tri-unsaturated, or polyunsaturated, or alkynyl. Unsaturated aliphatic groups can be in a cis- or trans-configuration. In certain embodiments, the aliphatic group contains from 1 to 12 carbon atoms, more generally from 1 to 6 carbon atoms or from 1 to 4 carbon atoms. In certain embodiments, the aliphatic group contains from 1 to 8 carbon atoms. In certain embodiments, the aliphatic group is C1-C2, C1-C3, C1-C4, C1-C5 or C1-C6. The specified ranges as used herein indicate an aliphatic group having each member of the range described as an independent species. For example, the term C1-C6 aliphatic as used herein indicates a straight or branched alkyl, alkenyl, or alkynyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each of these is described as an independent species. For example, the term C1-C4 aliphatic as usedP25-212-PRI-US01herein indicates a straight or branched alkyl, alkenyl, or alkynyl group having from 1, 2, 3, or 4 carbon atoms and is intended to mean that each of these is described as an independent species.

[0124] The term “heteroaliphatic” refers to an aliphatic moiety that contains at least one heteroatom in the chain, for example, an amine, carbonyl, carboxy, oxo, thio, phosphate, phosphonate, nitrogen, phosphorus, silicon, or boron atoms in place of a carbon atom. In certain embodiments, the only heteroatom is nitrogen. In certain embodiments, the only heteroatom is oxygen. In certain embodiments, the only heteroatom is sulfur. “Heteroaliphatic” is intended herein to include, but is not limited to, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, heterocycloalkenyl, and heterocycloalkynyl moieties. In certain embodiments, “heteroaliphatic” is used to indicate a heteroaliphatic group (cyclic, acyclic, branched or unbranched) having 1-20 carbon atoms. Nonlimiting examples of heteroaliphatic moieties are polyethylene glycol, polyalkylene glycol, amide, polyamide, polylactide, polyglycolide, thioether, ether, alkyl-heterocycle-alkyl, -O-alkyl-O-alkyl, and alkyl-O-haloalkyl.

[0125] The term optionally substituted may refer to one or more hydrogens of the designated moiety being replaced with a suitable substituent. Unless otherwise indicated, optionally substituted group has suitable substituent at each substitutable position of the group and when more than one position in any given structure is substituted with more than one substituent selected from the specified group, the substituent is either the same or different at every position. The substituent maybe any of the preceding groups as defined.

[0126] A “dosage form” means a unit of administration of an active agent. Examples of dosage forms include tablets, capsules, injections, suspensions, liquids, emulsions, implants, particles, spheres, creams, ointments, suppositories, inhalable forms, transdermal forms, buccal, sublingual, topical, gel, mucosal, and the like. A “dosage form” can also include an implant, for example an optical implant.

[0127] An “effective amount” as used herein, means an amount which provides a therapeutic benefit.

[0128] “Parenteral” administration of a pharmaceutical composition includes, e.g., subcutaneous (s.c.), intravenous (i.v.), intramuscular (i.m.), intrasternal injection, or infusion techniques.

[0129] Throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format isP25-212-PRI-US01merely for convenience and should not be construed as a limitation on the scope of the invention. The description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0130] As used herein, “pharmaceutical compositions” are compositions comprising at least one active agent, and at least one excipient.

[0131] The term “pharmaceutically acceptable” denotes an attribute of a material which is useful in preparing a pharmaceutical composition that is generally safe, nontoxic, and neither biologically nor otherwise undesirable and is acceptable for veterinary as well as human pharmaceutical use.

[0132] As used herein, “pharmaceutically acceptable salt” is a derivative of the disclosed compound in which the parent compound is modified by making inorganic and organic, non-toxic, acid or base addition salts thereof. The salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are typical, where practicable. Salts of the present compounds further include solvates of the compounds and of the compound salts.

[0133] Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric,P25-212-PRI-US01sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC-(CH2)n-COOH where n is 0-4, and the like, or using a different acid that produces the same counterion. Lists of additional suitable salts may be found, e.g., in Remington ’s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985).

[0134] The term “pharmaceutically acceptable auxiliary substance” refers to carriers and auxiliary substances such as diluents or excipients that are compatible with the other ingredients of the formulation.

[0135] A “patient” or “subject” is a human or non-human animal in need of treatment of any of the disorders as specifically described herein, for example that is modulated by a natural (wild-type) or modified (non-wild type) protein that can be degraded according to the present invention, resulting in a therapeutic effect. As described further herein, the word patient or subject typically refers to a human patient or subject unless it is clear from the context or wording that the disclosure is meant to include a non-human animal. Typically, the patient is a human. In other embodiments, the patient or subject is a non-human animal in need of such therapy and responsive thereto.

[0136] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. In the specification, singular forms also include the plural unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference. The references cited herein are not admitted to be prior art to the claimed application. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.P25-212-PRI-US01II. COMPOUNDS OF THE PRESENT INVENTION

[0137] In certain embodiments the compound of the present invention is selectedP25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01

[0138] or a pharmaceutically acceptablesalt thereof.Embodiments of alkyl

[0139] In certain embodiments “alkyl” is a C1-C10alkyl, C1-C9alkyl, C1-C8alkyl, C1-C7alkyl, C1-C6alkyl, C1-C5alkyl, C1-C4alkyl, C1-C3alkyl, or C1-C2alkyl.

[0140] In certain embodiments “alkyl” has one carbon.

[0141] In certain embodiments “alkyl” has two carbons.

[0142] In certain embodiments “alkyl” has three carbons.

[0143] In certain embodiments “alkyl” has four carbons.

[0144] In certain embodiments “alkyl” has five carbons.

[0145] In certain embodiments “alkyl” has six carbons.

[0146] Non-limiting examples of “alkyl” include: methyl, ethyl, propyl, butyl, pentyl, and hexyl.P25-212-PRI-US01

[0147] Additional non-limiting examples of “alkyl” include: isopropyl, isobutyl, isopentyl, and isohexyl.

[0148] Additional non-limiting examples of “alkyl” include: sec-butyl, sec-pentyl, andsec-hexyl.

[0149] Additional non-limiting examples of “alkyl” include: tert-butyl, tert-pentyl, andtert-hexyl.

[0150] Additional non-limiting examples of “alkyl” include: neopentyl, 3-pentyl, and active pentyl.Embodiments of cycloalkyl

[0151] In certain embodiments “cycloalkyl” is a C3-C8cycloalkyl, C3-C7cycloalkyl, C3-C6cycloalkyl, C3-C5cycloalkyl, C3-C4cycloalkyl, C4-C8cycloalkyl, C5-C8cycloalkyl, or C6-C8cycloalkyl.

[0152] In certain embodiments “cycloalkyl” has three carbons.

[0153] In certain embodiments “cycloalkyl” has four carbons.

[0154] In certain embodiments “cycloalkyl” has five carbons.

[0155] In certain embodiments “cycloalkyl” has six carbons.

[0156] In certain embodiments “cycloalkyl” has seven carbons.

[0157] In certain embodiments “cycloalkyl” has eight carbons.

[0158] In certain embodiments “cycloalkyl” has nine carbons.

[0159] In certain embodiments “cycloalkyl” has ten carbons.

[0160] Non-limiting examples of “cycloalkyl” include: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and cyclodecyl.Embodiments of haloalkyl

[0161] In certain embodiments “haloalkyl” is a Ci-Ciohaloalkyl, Ci-Cghaloalkyl, Ci-Cshaloalkyl, Ci-C?haloalkyl, C1-C6haloalkyl, Ci-Cshaloalkyl, Ci-C4haloalkyl, Ci-Cshaloalkyl, and Ci-C2haloalkyl.

[0162] In certain embodiments “haloalkyl” has one carbon.

[0163] In certain embodiments “haloalkyl” has one carbon and one halogen.

[0164] In certain embodiments “haloalkyl” has one carbon and two halogens.P25-212-PRI-US01

[0165] In certain embodiments “haloalkyl” has one carbon and three halogens.

[0166] In certain embodiments “haloalkyl” has two carbons.

[0167] In certain embodiments “haloalkyl” has three carbons.

[0168] In certain embodiments “haloalkyl” has four carbons.

[0169] In certain embodiments “haloalkyl” has five carbons.

[0170] In certain embodiments “haloalkyl” has six carbons.

[0171] Non-limiting examples of “haloalkyl” include:

[0172] Additional non-limiting examples of “haloalkyl” include:

[0173] Additional non-limiting examples of “haloalkyl” include:F F4-C|-H~

[0174] Additional non-limiting examples of “haloalkyl” include:Cl,Cl, andEmbodiments of heterocycle

[0175] In certain embodiments “heterocycle” refers to a cyclic ring with one nitrogen and 3, 4, 5, 6, 7, or 8 carbon atoms.

[0176] In certain embodiments “heterocycle” refers to a cyclic ring with one nitrogen and one oxygen and 3, 4, 5, 6, 7, or 8 carbon atoms.

[0177] In certain embodiments “heterocycle” refers to a cyclic ring with two nitrogens and 3, 4, 5, 6, 7, or 8 carbon atoms.P25-212-PRI-US01

[0178] In certain embodiments “heterocycle” refers to a cyclic ring with one oxygen and 3, 4, 5, 6, 7, or 8 carbon atoms.

[0179] In certain embodiments “heterocycle” refers to a cyclic ring with one sulfur and 3, 4, 5, 6, 7, or 8 carbon atoms.

[0180] Non-limiting examples of “heterocycle” include aziridine, oxirane, thiirane, azetidine, 1,3 -diazetidine, oxetane, and thietane.

[0181] Additional non-limiting examples of “heterocycle” include pyrrolidine, 3-pyrroline, 2-pyrroline, pyrazolidine, and imidazolidine.

[0182] Additional non-limiting examples of “heterocycle” include tetrahydrofuran, 1,3 -di oxolane, tetrahydrothiophene, 1,2-oxathiolane, and 1,3 -oxathiolane.

[0183] Additional non-limiting examples of “heterocycle” include piperidine, piperazine, tetrahydropyran, 1,4-di oxane, thiane, 1,3-dithiane, 1,4-dithiane, morpholine, and thiomorpholine.

[0184] Additional non-limiting examples of “heterocycle” include indoline, tetrahydroquinoline, tetrahydroisoquinoline, and dihydrobenzofuran wherein the point of attachment for each group is on the heterocycle ring.

[0185] Non-limiting examples of “heterocycle” also include:

[0186] Additional non-limiting examples of “heterocycle” include:

[0187] Additional non-limiting examples of “heterocycle” include:

[0188] Non-limiting examples of “heterocycle” also include:P25-212-PRI-US01

[0189] Non-limiting examples of “heterocycle” also include:

[0190] Additional non-limiting examples of “heterocycle” include:

[0191] Additional non-limiting examples of “heterocycle” include:Embodiments of heteroaryl

[0192] In certain embodiments “heteroaryl” is a 5 membered aromatic group containing 1, 2, 3, or 4 nitrogen atoms.

[0193] Non-limiting examples of 5 membered “heteroaryl” groups include pyrrole, furan, thiophene, pyrazole, imidazole, triazole, tetrazole, isoxazole, oxazole, oxadiazole, oxatriazole, isothiazole, thiazole, thiadiazole, and thiatriazole.

[0194] Additional non-limiting examples of 5 membered “heteroaryl” groups include:P25-212-PRI-US01

[0195] In certain embodiments “heteroaryl” is a 6 membered aromatic group containing 1, 2, or 3 nitrogen atoms (i.e. pyridinyl, pyridazinyl, triazinyl, pyrimidinyl, and pyrazinyl).

[0196] Non-limiting examples of 6 membered “heteroaryl” groups with 1 or 2 nitrogen atoms include:

[0197] In certain embodiments “heteroaryl” is a 9 membered bicyclic aromatic group containing 1 or 2 atoms selected from nitrogen, oxygen, and sulfur.

[0198] Non-limiting examples of “heteroaryl” groups that are bicyclic include indole, benzofuran, isoindole, indazole, benzimidazole, azaindole, azaindazole, purine, isobenzofuran, benzothiophene, benzoisoxazole, benzoisothiazole, benzooxazole, and benzothiazole.

[0199] Additional non-limiting examples of “heteroaryl” groups that are bicyclic

[0200] Additional non-limiting examples of “heteroaryl” groups that are bicyclic include:

[0201] Additional non-limiting examples of “heteroaryl” groups that are bicyclic include:P25-212-PRI-US01

[0202] In certain embodiments “heteroaryl” is a 10 membered bicyclic aromatic group containing 1 or 2 atoms selected from nitrogen, oxygen, and sulfur.

[0203] Non-limiting examples of “heteroaryl” groups that are bicyclic include quinoline, isoquinoline, quinoxaline, phthalazine, quinazoline, cinnoline, and naphthyridine.

[0204] Additional non-limiting examples of “heteroaryl” groups that are bicyclic include:cc5Embodiments of aryl

[0205] In certain embodiments aryl is phenyl.

[0206] In certain embodiments aryl is napthyl.Embodiments of bicycle

[0207] The term “bicycle” refers to a ring system wherein two rings share at least one atom in common. These rings can be spirocyclic or fused together and each ring is independently selected from carbocycle, heterocycle, aryl, and heteroaryl. Nonlimiting examples of bicycle groups include:

[0208] When the term “bicycle” is used in the context of a bivalent residue such as Linker the attachment points can be on separate rings or on the same ring. In certain embodiments both attachment points are on the same ring. In certain embodimentsP25-212-PRI-US01both attachment points are on different rings. Non-limiting examples of bivalent bicycle groups include:

[0209] Additional non-limiting examples of bivalent bicycle include:Embodiments of optional substituents

[0210] In certain embodiments wherein a variable can be optionally substituted it is not substituted.

[0211] In certain embodiments wherein a variable can be optionally substituted it is substituted with 1 substituent.

[0212] In certain embodiments wherein a variable can be optionally substituted it is substituted with 2 substituents.

[0213] In certain embodiments wherein a variable can be optionally substituted it is substituted with 3 substituents.

[0214] In certain embodiments wherein a variable can be optionally substituted it is substituted with 4 substituents.Embodiments of Aliphatic and Heteroaliphatic

[0215] In certain embodiments “aliphatic” refers to a saturated or unsaturated, straight, branched, or cyclic hydrocarbon. In these embodiments aliphatic is intended to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties, and thus incorporates each of these definitions. In certain embodiments, "aliphatic" is used to indicate those aliphatic groups having 1-20P25-212-PRI-US01carbon atoms. The aliphatic chain can be, for example, mono-unsaturated, diunsaturated, tri -unsaturated, or polyunsaturated, or alkynyl. Unsaturated aliphatic groups can be in a cis or trans configuration. In certain embodiments, the aliphatic group contains from 1 to about 12 carbon atoms, more generally from 1 to about 6 carbon atoms or from 1 to about 4 carbon atoms. In certain embodiments, the aliphatic group contains from 1 to about 8 carbon atoms. In certain embodiments, the aliphatic group is C1-C2, C1-C3, C1-C4, C1-C5 or C1-C6. The specified ranges as used herein indicate an aliphatic group having each member of the range described as an independent species. For example, the term C1-C6 aliphatic as used herein indicates a straight or branched alkyl, alkenyl, or alkynyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each of these is described as an independent species. For example, the term C1-C4 aliphatic as used herein indicates a straight or branched alkyl, alkenyl, or alkynyl group having from 1, 2, 3, or 4 carbon atoms and is intended to mean that each of these is described as an independent species. In certain embodiments, the aliphatic group is substituted with one or more functional groups that results in the formation of a stable moiety.

[0216] In certain embodiments "heteroaliphatic" refers to an aliphatic moiety that contains at least one heteroatom in the chain, for example, an amine, carbonyl, carboxy, oxo, thio, phosphate, phosphonate, nitrogen, phosphorus, silicon, or boron atoms in place of a carbon atom. In certain embodiments, the only heteroatom is nitrogen. In certain embodiments, the only heteroatom is oxygen. In certain embodiments, the only heteroatom is sulfur. In certain embodiments “heteroaliphatic" is intended herein to include, but is not limited to, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, heterocycloalkenyl, and heterocycloalkynyl moieties. In certain embodiments, "heteroaliphatic" is used to indicate a heteroaliphatic group (cyclic, acyclic, substituted, unsubstituted, branched or unbranched) having 1-20 carbon atoms. In certain embodiments, the heteroaliphatic group is optionally substituted in a manner that results in the formation of a stable moiety. Nonlimiting examples of heteroaliphatic moieties are polyethylene glycol, polyalkylene glycol, amide, polyamide, polylactide, polyglycolide, thioether, ether, alkyl-heterocycle-alkyl, -O-alkyl-O-alkyl, alkyl-O-haloalkyl, etc.

[0217] Solid tumors that can be treated with the compounds described herein include, but are not limited to lung cancers, including small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC), breast cancers including inflammatory breast cancer,P25-212-PRI-US01ER-positive breast cancer including tamoxifen resistant ER-positive breast cancer, and triple negative breast cancer, colon cancers, midline carcinomas, liver cancers, renal cancers, prostate cancers including castrate resistant prostate cancer (CRPC), brain cancers including gliomas, glioblastomas, neuroblastoma, and medulloblastoma including MYC-amplified medulloblastoma, colorectal cancers, Wilm's tumor, Ewing's sarcoma, rhabdomyosarcomas, ependymomas, head and neck cancers, melanomas, squamous cell carcinomas, ovarian cancers, pancreatic cancers including pancreatic ductal adenocarcinomas (PDAC) and pancreatic neuroendocrine tumors (PanNET), osteosarcomas, giant cell tumors of bone, thyroid cancers, bladder cancers, urothelial cancers, vulval cancers, cervical cancers, endometrial cancers, mesotheliomas, esophageal cancers, salivary gland cancers, gastric cancer, nasopharyngeal cancers, buccal cancers, cancers of the mouth, GIST (gastrointestinal stromal tumors), NUT-midline carcinomas, testicular cancers, squamous cell carcinomas, hepatocellular carcinomas (HCC), MYCN driven solid tumors, and NUT midline carcinomas (NMC). In certain embodiments, the disease or disorder is multiple myeloma.

[0218] In certain embodiments, the hematological cancer is acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), lymphoblastic T-cell leukemia, chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), hairy-cell leukemia, chronic neutrophilic leukemia (CNL), acute lymphoblastic T-cell leukemia, acute monocytic leukemia, plasmacytoma, immunoblastic large cell leukemia, mantle cell leukemia, multiple myeloma, megakaryoblastic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, mixed lineage leukemia (MLL), erythroleukemia, malignant lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, lymphoblastic T-cell lymphoma, Burkitt's lymphoma, follicular lymphoma, B cell acute lymphoblastic leukemia, diffuse large B cell lymphoma, Myc and B-Cell Leukemia (BCL)2 and / or BCL6 rearrangements / overexpression [double- and triple-hit lymphoma], myelodysplastic / myeloproliferative neoplasm, mantle cell lymphoma including bortezomib resistant mantle cell lymphoma.

[0219] In certain embodiments, the disease or disorder is sarcoma of the bones, muscles, tendons, cartilage, nerves, fat, or blood vessels. In certain embodiments, the disease or disorder is soft tissue sarcoma, bone sarcoma, or osteosarcoma. In certain embodiments, the disease or disorder is angiosarcoma, fibrosarcoma, liposarcoma,P25-212-PRI-US01leiomyosarcoma, Kaposi’s sarcoma, osteosarcoma, gastrointestinal stromal tumor, synovial sarcoma, pleomorphic sarcoma, chondrosarcoma, Ewing's sarcoma, reticulum cell sarcoma, meningiosarcoma, botryoid sarcoma, rhabdomyosarcoma, or embryonal rhabdomyosarcoma.COMBINATION THERAPY

[0220] A compound described herein or a pharmaceutically acceptable salt thereof can be used in an effective amount alone or in combination with another bioactive agent or second therapeutic agent to treat a human patient with a POLQ mediated disorder.

[0221] The term “bioactive agent” is used to describe an agent, other than the selected compound according to the present invention, which can be used in combination or alternation with a compound of the present invention to achieve a desired result of therapy. In certain embodiments, the compound of the present invention and the bioactive agent are administered in a manner that they are active in vivo during overlapping time periods, for example, have time-period overlapping Cmax, Tmax, AUC or another pharmacokinetic parameter. In another embodiment, the compound of the present invention and the bioactive agent are administered to a patient in need thereof that do not have overlapping pharmacokinetic parameter, however, one has a therapeutic impact on the therapeutic efficacy of the other.MAPK Inhibitors

[0222] In certain embodiments, the bioactive agent is an inhibitor of a protein involved in signaling through the mitogen-associated protein kinase (MAPK) pathway. Proteins involved in MAPK signaling include but are not limited to EGFR, SOS (including but not limited to S0S1), RAS (including but not limited to KRAS, NRAS, and HRAS), SHP2, RAF (including but not limited to BRAF), MEK (including but not limited to MEK1 and MEK2) and ERK.EGFR

[0223] In certain embodiments, the bioactive agent is an epidermal growth factor receptor (EGFR) inhibitor, including, for example gefitinib (Iressa), erlotinib (Tarceva), lapatinib (Tykerb), osimertinib (Tagrisso), neratinib (Nerlynx), vandetanib (Caprelsa), dacomitinib (Vizimpro), rociletinib (Xegafri), afatinib (Glotriff, Giotriff,P25-212-PRI-US01Afanix), lazertinib, or nazartib. Additional examples of EGFR inhibitors include rociletinib (CO- 1686), olmutinib (Olita), naquotinib (ASP8273), nazartinib (EGF816), PF-06747775, icotinib (BPI-2009), neratinib (HKI-272; PB272); avitinib (AC0010), EAI045, tarloxotinib (TH-4000; PR-610), PF-06459988 (Pfizer), tesevatinib (XL647; EXEL-7647; KD-019), transtinib, WZ-3146, WZ8040, CNX-2006, dacomitinib (PF-00299804; Pfizer), brigatinib (Alunbrig), lorlatinib, and PF-06747775 (PF7775).

[0224] In certain embodiments, the bioactive agent is a first-generation EGFR inhibitor such as erlotinib, gefitinib, or lapatinib. In certain embodiments, the bioactive agent is a second-generation EGFR inhibitor such as afatinib and / or dacomitinib. In certain embodiments, the bioactive agent is a third-generation EGFR inhibitor such as osimertinib.

[0225] In certain embodiments a compound of the present invention is administered to a patient in need thereof in combination with an anti-EGFR antibody, for example, cetuximab, panitumab, or necitumab.

[0226] In certain embodiments a compound of the present invention is administered to a patient in need thereof in combination with cetuximab.

[0227] In certain embodiments a compound of the present invention is administered to a patient in need thereof in combination with panitumab.

[0228] In certain embodiments a compound of the present invention is administered to a patient in need thereof in combination with necitumab.

[0229] In certain embodiments a compound of the present invention is administered to a patient in need thereof in combination with avelumab.SOS

[0230] In certain embodiments, the bioactive agent is a son of sevenless (SOS) inhibitor. In certain embodiments, the bioactive agent is a S0S1 inhibitor, including but not limited to BI-1701963, RGT-018, MRTX-0902, BAY-293, BI-3406, S0S1-IN-9,RAS

[0231] In certain embodiments, the bioactive agent is a rat sarcoma virus (RAS) protein inhibitor. Examples of RAS inhibitors include but are not limited to rigosertib, RMC-6236, Reolysin and siG12D LODER. In certain embodiments, the bioactiveP25-212-PRI-US01agent is an additional KRAS inhibitor. Nonlimiting examples of KRAS inhibitors include sotorasib, adagradib, JDQ443, D-1553, mRNA-5671, JAB-21822, IBI351, GFH925, LY3537982, ELI-002, ASP3082, RMC-6291, ERAS-3490, IMM-1-104, and GDC-6036. In certain embodiments, the bioactive agent is an NRAS inhibitor. In certain embodiments, the bioactive agent is an HRAS inhibitor.SHP2

[0232] In certain embodiments, the bioactive agent is a Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor. Examples of SHP2 inhibitors include but are not limited to BBP-398, SHP099, PF-07284892 (ARRY-558), RG6433, JAB-3068, JAB-3312, ERAS-601, HBI-2376, SH3809, ET0038, BPI-442096, TNO155, RMC-4630, RMC-4550, and RLY-1971. Additional SHP-2 inhibitors can be found in U. S. Patent No. 11,634,417.RAF

[0233] In certain embodiments, the bioactive agent is a Raf inhibitor. Raf inhibitors are known and include, for example, Vemurafinib (N-[3-[[5-(4-Chlorophenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-l-propanesulfonamide), sorafenib tosylate (4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide;4-methylbenzenesulfonate), AZ628 (3-(2-cyanopropan-2-yl)-N-(4-methyl-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)benzamide), NVP-BHG712 (4-methyl-3-(l -methyl -6-(pyri din-3 -yl)- lH-pyrazolo[3, 4-d]pyrimidin- 4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide), RAF-265 (l-methyl-5-[2-[5-(tri fluoromethyl)- lH-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine), 2 -Bromoal disine (2-Bromo-6,7-dihydro-lH,5H-pyrrolo[2,3-c]azepine-4, 8-dione), Raf Kinase Inhibitor IV (2-chloro- 5-(2-phenyl-5-(pyridin-4-yl)-lH-imidazol-4-yl)phenol), Sorafenib N-Oxide (4-[4-[[[[4-Chloro-3(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]phenoxy]-N-Methyl-2pyridinecarboxaMide 1 -Oxide), PLX-4720, vemurafenib, dabrafenib(GSK2118436), GDC-0879, RAF265, AZ 628, SB590885, ZM336372, GW5074, TAK-632, CEP-32496, LY3009120, and GX818 (Encorafenib).

[0234] In certain embodiments, the bioactive agent is a dual RAF / MEK inhibitor such as Avutometinib (RO5126766, CH5126766, VS-6766, CKI-27, R-7304, RG-7304).P25-212-PRI-US01MEK

[0235] In certain embodiments, the bioactive agent is a mitogen-activated protein kinase kinase (MEK, MAP2K, MAPKK) inhibitor. MEK inhibitors are well known, and include, for example, trametinib / GSK1120212 (N-(3-{3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H-yl}phenyl)acetamide), selumetinib (6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide), pimasertib / AS703026 / MSC 1935369 ((S)-N-(2,3-dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)isonicotinamide), XL-518 / GDC-0973 (1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S)-piperidin-2-yl]azetidin-3-ol), refametinib / BAY869766 / RDEA119 (N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-m ethoxyphenyl)- 1 -(2,3 -dihydroxypropyl)cyclopropane- 1 -sulfonamide), PD-0325901 (N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]- benzamide), TAK733 ((R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione), MEK162 / ARRY438162 (5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2- hydroxy ethoxy)- 1 -methyl- lH-benzimidazole-6-carboxamide), R05126766 (3-[[3-Fluoro-2-(methylsulfamoylamino)-4-pyridyl]methyl]-4-methyl-7-pyrimidin-2-yloxychromen-2-one), WX-554, R04987655 / CH4987655 (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-5-((3-oxo-l,2-oxazinan-2yl)methyl)benzamide), or AZD8330 (2-((2-fluoro-4-iodophenyl)amino)-N-(2 hydroxy ethoxy)- l,5-dimethyl-6-oxo-l,6-dihydropyridine-3-carboxamide), U0126-EtOH, PD184352 (CI-1040), GDC-0623, BI-847325, cobimetinib, PD98059, BIX 02189, BIX 02188, binimetinib, SL-327, TAK-733, PD318088.ER Ik

[0236] In certain embodiments, the bioactive agent is an extracellular signal-regulated kinase (ERK) inhibitor, including ERK1 and ERK2 inhibitors. Nonlimiting examples of ERK inhibitors include Ulixertinib (BVD-523, VRT752271), VX-11e (4-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-N-(l-(3-chlorophenyl)-2-hydroxyethyl)-lH-pyrrole-2-carboxamide), AZD0364, MK-8353 (SCH900353), LY3214996, CC-9003, BIX-02189, SCH772984, ASN007, MRTX-1257, ERK5-IN-2, AZD0364 (ATG-017), and FR180204.P25-212-PRI-US01Immunotherapeutics

[0237] In certain aspects of this embodiment, the bioactive agent is an immune modulator, including but not limited to a checkpoint inhibitor, including as nonlimiting examples, aPD-1 inhibitor, PD-L1 inhibitor, PD-L2 inhibitor, CTLA-4 inhibitor, LAG-3 inhibitor, TIM-3 inhibitor, V-domain Ig suppressor of T-cell activation (VISTA) inhibitors, small molecule, peptide, nucleotide, or other inhibitor. In certain aspects, the immune modulator is an antibody, such as a monoclonal antibody.

[0238] PD-1 inhibitors that blocks the interaction of PD-1 and PD-L1 by binding to the PD-1 receptor, and in turn inhibit immune suppression include, for example, nivolumab (Opdivo), pembrolizumab (Keytruda), pidilizumab, AMP-224 (AstraZeneca and Medlmmune), PF-06801591 (Pfizer), MEDI0680 (AstraZeneca), PDR001 (Novartis), REGN2810 (Regeneron), SHR-12-1 (Jiangsu Hengrui Medicine Company and Incyte Corporation), TSR-042 (Tesaro), and the PD-L1 / VISTA inhibitor CA-170 (Curis Inc.). PD-L1 inhibitors that block the interaction of PD-1 and PD-L1 by binding to the PD-L1 receptor, and in turn inhibits immune suppression, include for example, atezolizumab (Tecentriq), durvalumab (AstraZeneca and Medlmmune), KN035 (Alphamab), and BMS-936559 (Bristol-Myers Squibb).CTLA-4 checkpoint inhibitors that bind to CTLA-4 and inhibits immune suppression include, but are not limited to, ipilimumab, tremelimumab (AstraZeneca and Medlmmune), AGEN1884 and AGEN2041 (Agenus). LAG-3 checkpoint inhibitors include, but are not limited to, BMS-986016 (Bristol-Myers Squibb), GSK2831781 (GlaxoSmithKline), IMP321 (Prima BioMed), LAG525 (Novartis), and the dual PD-1 and LAG-3 inhibitor MGD013 (MacroGenics). An example of a TIM-3 inhibitor is TSR-022 (Tesaro).

[0239] In certain embodiments, the PD-L1 inhibitor is a small molecule PD-L1 inhibitor including but not limited to INCB99280, BMS-202, BMS-1001, BMS-1166, CA-170, TPP-1, AUNP-12, and DPPA-1.

[0240] In certain embodiments the checkpoint inhibitor is selected from nivolumab / OPDIVO®; pembrolizumab / KEYTRUDA®; and pidilizumab / CT-011, MPDL3280A / RG7446; MEDI4736; MSB0010718C; BMS 936559, a PDL2 / lg fusion protein such as AMP 224 or an inhibitor of B7-H3 (e.g., MGA271 ), B7-H4, BTLA,P25-212-PRI-US01HVEM, TIM3, GAL9, LAG 3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7 family ligands, or a combination thereof.

[0241] In another embodiment, one of the active compounds described herein can be administered in an effective amount for the treatment of abnormal tissue of the female reproductive system such as breast, ovarian, endometrial, or uterine cancer, in combination or alternation with an effective amount of an estrogen inhibitor including, but not limited to, a SERM (selective estrogen receptor modulator), a SERD (selective estrogen receptor degrader), a complete estrogen receptor degrader, or another form of partial or complete estrogen antagonist or agonist. Partial antiestrogens like raloxifene and tamoxifen retain some estrogen-like effects, including an estrogen-like stimulation of uterine growth, and also, in some cases, an estrogen-like action during breast cancer progression which actually stimulates tumor growth. In contrast, fulvestrant, a complete anti-estrogen, is free of estrogen-like action on the uterus and is effective in tamoxifen-resistant tumors.

[0242] Non-limiting examples of anti-estrogen compounds are provided in WO201419176 assigned to Astra Zeneca, WO2013090921, WO 2014203129, WO2014203132, and US2013 / 0178445 assigned to Olema Pharmaceuticals, and U. S. Patent Nos. 9,078,871, 8,853,423, and 8,703, 810, as well as US20150005286, WO2014205136, and WO2014205138.

[0243] Additional non-limiting examples of anti-estrogen compounds include:SERMS such as anordrin, bazedoxifene, broparestriol, chlorotrianisene, clomiphene citrate, cyclofenil, lasofoxifene, ormeloxifene, raloxifene, tamoxifen, toremifene, and fulvestratnt; aromatase inhibitors such as aminoglutethimide, testolactone, anastrozole, exemestane, fadrozole, formestane, and letrozole; and antigonadotropins such as leuprorelin, cetrorelix, allylestrenol, chloromadinone acetate, cyproterone acetate, delmadinone acetate, dydrogesterone, medroxyprogesterone acetate, megestrol acetate, nomegestrol acetate, nor ethisterone acetate, progesterone, and spironolactone.

[0244] Other estrogenic ligands that can be used according to the present invention are described in U. S. Patent Nos. 4,418,068; 5,478,847; 5,393,763; and 5,457,117, WO2011 / 156518, US Patent Nos. 8,455,534 and 8,299,112, U. S. Patent Nos.9,078,871; 8,853,423; 8,703,810; US 2015 / 0005286; and WO 2014 / 205138, US2016 / 0175289, US2015 / 0258080, WO2014191726, W02012084711;W02002013802; W02002004418; W02002003992; W02002003991;P25-212-PRI-US01W02002003990; W02002003989; W02002003988; W02002003986;W02002003977; W02002003976; W02002003975; W02006078834; US 6821989; US 2002 / 0128276; US 6777424; US 2002 / 0016340; US 6326392; US 6756401; US 2002 / 0013327; US 6512002; US 6632834; US 2001 / 0056099; US 6583170; US 6479535; WO1999024027; US 6005102; EP 0802184; US 5998402; US 5780497, US 5880137, W02012048058 and W02007087684.

[0245] In another embodiment, active compounds described herein can be administered in an effective amount for the treatment of abnormal tissue of the male reproductive system such as prostate or testicular cancer, in combination or alternation with an effective amount of an androgen (such as testosterone) inhibitor including, but not limited to a selective androgen receptor modulator, a selective androgen receptor degrader, a complete androgen receptor degrader, or another form of partial or complete androgen antagonist. In certain embodiments, the prostate or testicular cancer is androgen-resistant.

[0246] Non-limiting examples of anti-androgen compounds are provided in WO 2011 / 156518 and US Patent Nos. 8,455,534 and 8,299,112. Additional non-limiting examples of anti-androgen compounds include: enzalutamide, apalutamide, cyproterone acetate, chlormadinone acetate, spironolactone, canrenone, drospirenone, ketoconazole, topilutamide, abiraterone acetate, and cimetidine.

[0247] In certain embodiments, the bioactive agent is an ALK inhibitor. Examples of ALK inhibitors include but are not limited to Crizotinib, Alectinib, ceritinib, TAE684 (NVP-TAE684), GSK1838705A, AZD3463, ASP3026, PF-06463922, entrectinib (RXDX-101), and AP26113.

[0248] In certain embodiments, the bioactive agent is an HER-2 inhibitor. Examples of HER-2 inhibitors include trastuzumab, lapatinib, ado-trastuzumab emtansine, and pertuzumab.

[0249] In certain embodiments, the bioactive agent is a CD20 inhibitor. Examples of CD20 inhibitors include obinutuzumab, rituximab, fatumumab, ibritumomab, tositumomab, and ocrelizumab.

[0250] In certain embodiments, the bioactive agent is a JAK3 inhibitor. Examples of JAK3 inhibitors include tasocitinib.

[0251] In certain embodiments, the bioactive agent is a BCL-2 inhibitor. Examples of BCL-2 inhibitors include venetoclax, ABT-199 (4-[4-[[2-(4-Chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl]piperazin-l-yl]-N-[[3-nitro-4-[[(tetrahydro-2H-P25-212-PRI-US01pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-[(lH- pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide), ABT-737 (4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-l-yl]-N-[4- [[(2R)-4-(dimethylamino)-l-phenylsulfanylbutan-2-yl] amino]-3-nitrophenyl]sulfonylbenzamide) (navitoclax), ABT-263 ((R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[l, l'-biphenyl]-2-yl)methyl)piperazin-l-yl)-N-((4-((4-morpholino- 1 -(phenylthio)butan-2-yl)amino)-3((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide), GX15-070 (obatoclax mesylate, (2Z)-2- [(5Z)-5 - [(3,5- dimethyl -lH-pyrrol-2-yl)methylidene] -4-methoxypyrrol-2-ylidene]indole; methanesulfonic acid))), 2-methoxy-antimycin A3, YC137 (4-(4,9-dioxo-4,9-dihydronaphtho[2,3-d]thiazol-2-ylamino)-phenyl ester), pogosin, ethyl 2-amino-6-bromo-4-(l-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate, Nilotinib-d3, TW-37 (N-[4-[[2-(l, 1- Dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-trihydroxy-5-[[2-(l-methylethyl)phenyl]methyl]benzamide), Apogossypolone (ApoG2), HA14-1, AT101, sabutoclax, gambogic acid, or G3139 (Oblimersen).

[0252] In certain embodiments, the bioactive agent is a kinase inhibitor. In certain embodiments, the kinase inhibitor is selected from a phosphoinositide 3-kinase (PI3K) inhibitor, a Bruton’s tyrosine kinase (BTK) inhibitor, or a spleen tyrosine kinase (Syk) inhibitor, or a combination thereof.

[0253] Examples of PI3 kinase inhibitors include, but are not limited to, Wortmannin, demethoxyviridin, perifosine, idelalisib, Pictilisib, Palomid 529, ZSTK474, PWT33597, CUDC-907, and AEZS-136, duvelisib, GS-9820, BKM120, GDC-0032 (Taselisib) (2-[4-[2-(2-Isopropyl-5-methyl-l,2,4-triazol-3-yl)-5,6-dihydroimidazo[ 1,2-d] [ 1,4]benzoxazepin-9-yl]pyrazol- 1 -yl]-2-methylpropanamide), MLN-1117 ((2R)-l-Phenoxy-2-butanyl hydrogen (S)-methylphosphonate; or Methyl(oxo) {[(2R)-l-phenoxy-2-butanyl]oxy}phosphonium)), BYL-719 ((2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-l,l-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-l,2-pyrrolidinedicarboxamide), GSK2126458 (2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide) (omipalisib), TGX-221 ((±)-7-Methyl-2-(morpholin-4-yl)-9-(l-phenylaminoethyl)-pyrido[l,2-a]-pyrimi din-4-one), GSK2636771 (2 -Methyl- l-(2-methyl-3 -(trifluoromethyl)benzyl)-6-morpholino-lH-benzo[d]imidazole-4-carboxylic acid dihydrochloride), KIN-193 ((R)-2-((l-(7-methyl-2-morpholino-4-oxo-4H-pyrido[l,2-a]pyrimidin-9-yl)ethyl)amino)benzoic acid), TGR-1202 / RP5264, GS-9820 ((S)- l-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-P25-212-PRI-US014-mohydroxypropan- 1 -one), GS-1101 (5-fluoro-3-phenyl-2-([S)]-l-[9H-purin-6-ylamino]-propyl)-3H-quinazolin-4-one), AMG-319, GSK-2269557, SAR245409 (N-(4-(N-(3 -((3, 5 -dimethoxyphenyl)amino)quinoxalin-2-yl)sulfamoyl)phenyl)-3 -methoxy-4 methylbenzamide), BAY80-6946 (2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[l,2-c]quinaz), AS 252424 (5-[l-[5-(4-Fluoro-2-hydroxy-phenyl)-furan-2-yl]-meth-(Z)-ylidene]-thiazolidine-2, 4-dione), CZ 24832 (5-(2-amino-8-fluoro-[l,2,4]triazolo[l,5-a]pyridin-6-yl)-N-tert-butylpyridine-3-sulfonamide), Buparlisib (5-[2,6-Di(4-morpholinyl)-4- pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine), GDC-0941 (2-(lH-Indazol-4-yl)-6-[[4-(methylsulfonyl)-l-piperazinyl]methyl]-4-(4-morpholinyl)thieno[3,2-d]pyrimidine), GDC-0980 ((S)-l-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6 yl)methyl)piperazin-l-yl)-2-hydroxypropan-l-one (also known as RG7422)), SF1126 ((8S,14S,17S)-14-(carboxymethyl)-8-(3-guanidinopropyl)-17-(hydroxymethyl)-3,6,9,12,15-pentaoxo-l-(4-(4-oxo-8-phenyl-4H-chromen-2-yl)morpholino-4-ium)-2-oxa-7, 10,13,16-tetraazaoctadecan- 18-oate), PF-05212384 (N-[4-[[4-(Dimethylamino)-l- piperidinyl]carbonyl]phenyl]-N'-[4-(4,6-di-4-morpholinyl-l,3,5-triazin-2-yl)phenyl]urea) (gedatolisib), LY3023414, BEZ235 (2-Methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-l-yl]phenyl}propanenitrile) (dactolisib), XL-765 (N-(3-(N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide), and GSK1059615 (5-[[4-(4-Pyridinyl)-6-quinolinyl]methylene]-2,4-thiazolidenedione), PX886 ([(3aR,6E,9S,9aR,10R,l laS)-6-[[bis(prop-2-enyl)amino]methylidene]-5-hydroxy-9-(methoxymethyl)-9a,l la-dimethyl-1,4,7-trioxo-2,3,3a,9,10,ll-hexahydroindeno [4,5h]isochromen- 10-yl] acetate (also known as sonolisib)), LY294002, AZD8186, PF-4989216, pilaralisib, GNE-317, PI-3065, PI-103, NU7441 (KU-57788), HS 173, VS-5584 (SB2343), CZC24832, TG100-115, A66, YM201636, CAY10505, PIK-75, PIK-93, AS-605240, BGT226 (NVP-BGT226), AZD6482, voxtalisib, alpelisib, IC-87114, TGI100713, CH5132799, PKI-402, copanlisib (BAY 80-6946), XL 147, PIK-90, PIK-293, PIK-294, 3-MA (3-methyladenine), AS-252424, AS-604850, apitolisib (GDC-0980; RG7422).

[0254] Examples of BTK inhibitors include ibrutinib (also known as PCI-32765)(Imbruvica™)(l-[(3R)-3-[4-amino-3-(4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin- 1 -yl]piperidin- 1 -yl]prop-2-en- 1 -one), dianilinopyrimidine-based inhibitors such as AVL-101 and AVL-291 / 292 (N-(3-((5-fluoro-2-((4-(2-P25-212-PRI-US01methoxy ethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide) (Avila Therapeutics) (see US Patent Publication No 2011 / 0117073, incorporated herein in its entirety), Dasatinib ([N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-l-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide], LFM-A13 (alpha-cyano-beta-hydroxy -beta-methyl-N-(2,5-ibromophenyl) propenamide), GDC-0834 ([R-N-(3-(6-(4-(l,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4, 5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide], CGI-560 4-(tert-butyl)-N-(3-(8-(phenylamino)imidazo[ 1,2-a]pyrazin-6-yl)phenyl)benzamide, CGI- 1746 (4-(tert-butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide), CNX-774 (4-(4-((4-((3-acrylamidophenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenoxy)-N-methylpicolinamide), CTA056 (7-benzyl-l-(3-(piperidin-l-yl)propyl)-2-(4-(pyridin- 4-yl)phenyl)-lH-imidazo[4,5-g]quinoxalin-6(5H)-one), GDC-0834 ((R)-N-(3-(6-((4-(l,4-dimethyl-3-oxopiperazin-2-yl)phenyl)amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide), GDC-0837 ((R)-N-(3-(6-((4-(l,4-dimethyl-3-oxopiperazin-2-yl)phenyl)amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4, 5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide), HM-71224, ACP-196, ONO-4059 (Ono Pharmaceuticals), PRT062607 (4-((3-(2H-l,2,3-triazol-2-yl)phenyl)amino)-2-(((lR,2S)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide hydrochloride), QL-47 ( 1 -( 1 -acryloylindolin-6-yl)-9-( 1 -methyl- 1 H-pyrazol-4-yl)benzo[h][l,6]naphthyridin-2(lH)-one), and RN486 (6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{ l-methyl-5-[5-(4-methyl-piperazin-l-yl)-pyri din-2 -ylamino]-6-oxo-1, 6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-l-one), and other molecules capable of inhibiting BTK activity, for example those BTK inhibitors disclosed in Akinleye et ah, Journal of Hematology & Oncology, 2013, 6:59, the entirety of which is incorporated herein by reference.

[0255] Syk inhibitors include, but are not limited to, Cerdulatinib (4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-l-yl)phenyl)amino)pyrimidine- 5-carboxamide), entospletinib (6-(lH-indazol-6-yl)-N-(4-morpholinophenyl)imidazo[l,2-a]pyrazin-8-amine), fostamatinib ([6-({5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl}amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b] [ 1,4]oxazin-4-yl]methyl dihydrogen phosphate),P25-212-PRI-US01fostamatinib di sodium salt (sodium (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][l,4]oxazin-4(3H)-yl)methyl phosphate), BAY 61-3606 (2-(7-(3,4-Dimethoxyphenyl)-imidazo[l,2-c]pyrimidin-5-ylamino)-nicotinamide HC1), RO9021 (6-[(lR,2S)-2-Amino-cyclohexylamino]-4-(5,6-dimethyl-pyridin-2-ylamino)-pyridazine-3 -carboxylic acid amide), imatinib (Gleevac; 4-[(4-methylpiperazin-l-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide), staurosporine, GSK143 (2-(((3R,4R)-3-aminotetrahydro-2H-pyran-4-yl)amino)-4-(p-tolylamino)pyrimidine-5-carboxamide), PP2 (l-(tert-butyl)-3-(4-chlorophenyl)-lH-pyrazolo[3,4-d]pyrimidin-4-amine), PRT-060318 (2-(((lR,2S)-2-aminocyclohexyl)amino)-4-(m-tolylamino)pyrimidine-5-carboxamide), PRT-062607 (4-((3-(2H-l,2,3-triazol-2-yl)phenyl)amino)-2-(((lR,2S)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide hydrochloride), R112 (3,3'-((5-fluoropyrimidine-2,4-diyl)bis(azanediyl))diphenol), R348 (3 -Ethyl-4-m ethylpyridine), R406 (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][l,4]oxazin-3(4H)-one), piceatannol (3-Hydroxyresveratol), YM193306 (see Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643), 7-azaindole, piceatannol, ER-27319 (see Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643 incorporated in its entirety herein), Compound D (see Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643 incorporated in its entirety herein), PRT060318 (see Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643 incorporated in its entirety herein), luteolin (see Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643 incorporated in its entirety herein), apigenin (see Singh et al.Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643 incorporated in its entirety herein), quercetin (see Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643 incorporated in its entirety herein), fisetin (see Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643 incorporated in its entirety herein), myricetin (see Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors,P25-212-PRI-US01J. Med. Chem. 2012, 55, 3614-3643 incorporated in its entirety herein), morin (see Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643 incorporated in its entirety herein).

[0256] In certain embodiments, the bioactive agent is a c-MET inhibitor, for example, crizotinib (Xalkori, Crizonix), tepotinib (XL880, EXEL-2880, GSK1363089, GSK089), ortivantinib (ARQ197).

[0257] In certain embodiments, the bioactive agent is an AKT inhibitor, including, but not limited to, MK-2206, GSK690693, Perifosine, (KRX-0401), GDC-0068, Triciribine, AZD5363, Honokiol, PF-04691502, and Miltefosine, a FLT-3 inhibitor, including, but not limited to, P406, Dovitinib, Quizartinib (AC220), Amuvatinib (MP-470), Tandutinib (MLN518), ENMD-2076, and KW-2449, or a combination thereof.

[0258] In certain embodiments, the bioactive agent is an mTOR inhibitor. Examples of mTOR inhibitors include, but are not limited to, rapamycin and its analogs, everolimus (Afinitor), temsirolimus, ridaforolimus, sirolimus, and deforolimus.

[0259] In certain embodiments, the bioactive agent is an HSP inhibitor. HSP inhibitors include but are not limited to Geldanamycin or 17-N-Allylamino-17-demethoxygeldanamycin (17AAG), and Radicicol.

[0260] Additional bioactive compounds include, for example, everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, a FLT-3 inhibitor, a VKRAS inhibitor, an aurora kinase inhibitor, a PIK-1 modulator, an HD AC inhbitor, a c-MET inhibitor, a PARP inhibitor, a Cdk inhibitor, an IGFR-TK inhibitor, an anti-HGF antibody, a focal adhesion kinase inhibitor, a Map kinase kinase (MEK) inhibitor, a VEGF trap antibody, pemetrexed, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171, batabulin, of atumumab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdRl KRX-0402, lucanthone, LY317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, liposomal doxorubicin, 5 ' -deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709, seliciclib; PD0325901, AZD-P25-212-PRI-US016244, capecitabine, L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-lH-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt, heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrazole, exemestane, letrozole, DES(diethylstilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11, CHIR-258); 3-[5-(methylsulfonylpiperadinemethyl)-indolyl-quinolone, vatalanib, AG-013736, AVE-0005, goserelin acetate, leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF antibody, erbitux, EKB-569, PKI-166, GW-572016, lonafamib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoyl analide hydroxamic acid, valproic acid, trichostatin A, FK-228, SU11248, sorafenib, KRN951, aminoglutethimide, arnsacrine, anagrelide, L-asparaginase, Bacillus Calmette-Guerin (BCG) vaccine, adriamycin, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gleevec, gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, levamisole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deooxyuridine, cytosine arabinoside, 6-mecaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxin, marimastat, COL-3, neovastat, BMS-275291, squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin- 12, IM862, angiostatin, vitaxin, droloxifene, idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab, denileukin diftitox, gefitinib, bortezimib, paclitaxel, cremophor-free paclitaxel, docetaxel, epithilone B, BMS-247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene, fulvestrant, acolbifene, lasofoxifene, idoxifene, TSE-424, HMR-3339, ZK186619, topotecan, PTK787 / ZK 222584, VX-745, PD 184352, rapamycin, 40-0-(2-hydroxyethyl)-rapamycin, temsirolimus, AP -23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372,P25-212-PRI-US01L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colonystimulating factor, zolendronate, prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all-transretinoic acid, ketoconazole, interleukin-2, megestrol, immune globulin, nitrogen mustard, methylprednisolone, ibritgumomab tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, editronate, mitotane, cyclosporine, liposomal daunorubicin, Edwina-asparaginase, strontium 89, casopitant, netupitant, anNK-1 receptor antagonist, palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa, darbepoetin alfa and mixtures thereof.

[0261] In certain embodiments the compound is administered in combination with ifosfamide.

[0262] In certain embodiments, the bioactive agent is selected from, but are not limited to, Imatinib mesylate (Gleevac®), Dasatinib (Spry cel®), Nilotinib (Tasigna®), Bosutinib (Bosulif®), Trastuzumab (Herceptin®), trastuzumab-DMl, Pertuzumab (PerjetaTM), Lapatinib (Tykerb®), Gefitinib (Iressa®), Erlotinib (Tarceva®), Cetuximab (Erbitux®), Panitumumab (Vectibix®), Vandetanib (Caprelsa®), Vemurafenib (Zelboraf®), Vorinostat (Zolinza®), Romidepsin (Istodax®), Bexarotene (Tagretin®), Alitretinoin (Panretin®), Tretinoin (Vesanoid®), Carfilizomib (KyprolisTM), Pralatrexate (Folotyn®), Bevacizumab (Avastin®), Ziv-aflibercept (Zaltrap®), Sorafenib (Nexavar®), Sunitinib (Sutent®), Pazopanib (Votrient®), Regorafenib (Stivarga®), and Cabozantinib (CometriqTM).

[0263] In certain aspects, the bioactive agent is an anti-inflammatory agent, a chemotherapeutic agent, a radiotherapeutic, an additional therapeutic agent, or an immunosuppressive agent.

[0264] Suitable chemotherapeutic bioactive agents include, but are not limited to, a radioactive molecule, a toxin, also referred to as cytotoxin or cytotoxic agent, which includes any agent that is detrimental to the viability of cells, and liposomes or other vesicles containing chemotherapeutic compounds. General anticancer pharmaceutical agents include: Vincristine (Oncovin®) or liposomal vincristine (Marqibo®),P25-212-PRI-US01Daunorubicin (daunomycin or Cerubidine®) or doxorubicin (Adriamycin®), Cytarabine (cytosine arabinoside, ara-C, or Cytosar®), L-asparaginase (Elspar®) or PEG-L-asparaginase (pegaspargase or Oncaspar®), Etoposide (VP- 16), Teniposide (Vumon®), 6-mercaptopurine (6-MP or Purinethol®), Methotrexate, Cyclophosphamide (Cytoxan®), Prednisone, Dexamethasone (Decadron), imatinib (Gleevec®), dasatinib (Sprycel®), nilotinib (Tasigna®), bosutinib (Bosulif®), and ponatinib (Iclusig™).

[0265] Examples of additional suitable chemotherapeutic agents include, but are not limited to 1 -dehydrotestosterone, 5 -fluorouracil decarbazine, 6-mercaptopurine, 6-thioguanine, actinomycin D, adriamycin, aldesleukin, an alkylating agent, allopurinol sodium, altretamine, amifostine, anastrozole, anthramycin (AMC)), an anti-mitotic agent, cis-dichlorodiamine platinum (II) (DDP) cisplatin), diamino dichloro platinum, anthracycline, an antibiotic, an antimetabolite, asparaginase, BCG live (intravesical), betamethasone sodium phosphate and betamethasone acetate, bicalutamide, bleomycin sulfate, busulfan, calcium leucouorin, calicheamicin, capecitabine, carboplatin, lomustine (CCNU), carmustine (BSNU), Chlorambucil, Cisplatin, Cladribine, Colchicin, conjugated estrogens, Cyclophosphamide, Cyclothosphamide, Cytarabine, Cytarabine, cytochalasin B, Cytoxan, Dacarbazine, Dactinomycin, dactinomycin (formerly actinomycin), daunirubicin HC1, daunorucbicin citrate, denileukin diftitox, Dexrazoxane, Dibromomannitol, dihydroxy anthracin dione, Docetaxel, dolasetron mesylate, doxorubicin HC1, dronabinol, E. coli L-asparaginase, emetine, epoetin-α, Erwinia L-asparaginase, esterified estrogens, estradiol, estramustine phosphate sodium, ethidium bromide, ethinyl estradiol, etidronate, etoposide citrororum factor, etoposide phosphate, filgrastim, floxuridine, fluconazole, fludarabine phosphate, fluorouracil, flutamide, folinic acid, gemcitabine HC1, glucocorticoids, goserelin acetate, gramicidin D, granisetron HC1, hydroxyurea, idarubicin HC1, ifosfamide, interferon α-2b, irinotecan HC1, letrozole, leucovorin calcium, leuprolide acetate, levamisole HC1, lidocaine, lomustine, maytansinoid, mechlorethamine HC1, medroxyprogesterone acetate, megestrol acetate, melphalan HC1, mercaptipurine, mesna, methotrexate, methyltestosterone, mithramycin, mitomycin C, mitotane, mitoxantrone, nilutamide, octreotide acetate, ondansetron HC1, paclitaxel, pamidronate disodium, pentostatin, pilocarpine HC1, plimycin, polifeprosan 20 with carmustine implant, porfimer sodium, procaine, procarbazine HCL, propranolol, rituximab, sargramostim, streptozotocin, tamoxifen, taxol,P25-212-PRI-US01teniposide, tenoposide, testolactone, tetracaine, thioepa chlorambucil, thioguanine, thiotepa, topotecan HC1, toremifene citrate, trastuzumab, tretinoin, valrubicin, vinblastine sulfate, vincristine sulfate, and vinorelbine tartrate.

[0266] In some embodiments, the compound of the present invention is administered in combination with a chemotherapeutic agent (e.g., a cytotoxic agent or other chemical compound useful in the treatment of cancer). Examples of chemotherapeutic agents include alkylating agents, antimetabolites, folic acid analogs, pyrimidine analogs, purine analogs and related inhibitors, vinca alkaloids, epipodophyllotoxins, antibiotics, L-Asparaginase, topoisomerase inhibitors, interferons, platinum coordination complexes, anthracenedione substituted urea, methyl hydrazine derivatives, adrenocortical suppressant, adrenocorticosteroides, progestins, estrogens, antiestrogen, androgens, antiandrogen, and gonadotropin-releasing hormone analog. Also included is 5 -fluorouracil (5-FU), leucovorin (LV), irenotecan, oxaliplatin, capecitabine, paclitaxel, and doxetaxel. Non-limiting examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; cally statin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1 ); eleutherobin; pancrati statin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammall and calicheamicin omegall (see, e.g., Agnew, Chem. Inti. Ed Engl. 33:183-186 (1994)); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins,P25-212-PRI-US01cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo- 5-oxo-L-norleucine, ADRIAMYCIN® (doxorubicin, including morpholino-doxorubicin, cyanomorpholino- doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites such as methotrexate and 5 -fluorouracil (5- FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2, 2', 2"-trichlorotriethylamine; trichothecenes (especially T- 2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (" Ara-C"); cyclophosphamide; thiotepa; taxoids, e.g., TAXOL® (paclitaxel; Bristol-Myers Squibb Oncology, Princeton, NJ), ABRAXANE®, cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, IL), and TAXOTERE® doxetaxel (Rhone-Poulenc Rorer, Antony, France); chloranbucil; GEMZAR® gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE® vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-1 1 ); topoisomerase inhibitor RFS 2000;P25-212-PRI-US01difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Two or more chemotherapeutic agents can be used in a cocktail to be administered in combination with the compound of the present invention. Suitable dosing regimens of combination chemotherapies are known in the ar. For example combination dosing regimes are described in Saltz et al., Proc. Am. Soc. Clin. Oncol. 18:233a (1999) and Douillard et al., Lancet 355(9209): 1041 -1047 (2000).

[0267] Additional therapeutic agents that can be administered in combination with a Compound disclosed herein can include bevacizumab, sutinib, sorafenib, 2-methoxyestradiol or 2ME2, finasunate, vatalanib, vandetanib, aflibercept, volociximab, etaracizumab (MEDI-522), cilengitide, erlotinib, cetuximab, panitumumab, gefitinib, trastuzumab, dovitinib, figitumumab, atacicept, rituximab, alemtuzumab, aldesleukine, atlizumab, tocilizumab, temsirolimus, everolimus, lucatumumab, dacetuzumab, HLL1, huN901-DMl, atiprimod, natalizumab, bortezomib, carfilzomib, marizomib, tanespimycin, saquinavir mesylate, ritonavir, nelfinavir mesylate, indinavir sulfate, belinostat, panobinostat, mapatumumab, lexatumumab, dulanermin, ABT-737, oblimersen, plitidepsin, talmapimod, P276-00, enzastaurin, tipifarnib, perifosine, imatinib, dasatinib, lenalidomide, thalidomide, simvastatin, celecoxib, bazedoxifene, AZD4547, rilotumumab, oxaliplatin (Eloxatin), PD0332991, ribociclib (LEE011), amebaciclib (LY2835219), HDM201, fulvestrant (Faslodex), exemestane (Aromasin), PIM447, ruxolitinib (INC424), BGJ398, necitumumab, pemetrexed (Alimta), and ramucirumab (IMC-1121B).

[0268] In certain embodiments, the additional therapy is a monoclonal antibody (MAb). Some MAbs stimulate an immune response that destroys cancer cells. Similar to the antibodies produced naturally by B cells, these MAbs may “coat” the cancer cell surface, triggering its destruction by the immune system. For example, bevacizumab targets vascular endothelial growth factor (VEGF), a protein secreted by tumor cells and other cells in the tumor’s microenvironment that promotes the development of tumor blood vessels. When bound to bevacizumab, VEGF cannot interact with its cellular receptor, preventing the signaling that leads to the growth of new blood vessels. MAbs that bind to cell surface growth factor receptors prevent the targeted receptors from sending their normal growth-promoting signals. They may also trigger apoptosis and activate the immune system to destroy tumor cells.P25-212-PRI-US01

[0269] In certain aspects of the present invention, the bioactive agent is an immunosuppressive agent. The immunosuppressive agent can be a calcineurin inhibitor, e.g. a cyclosporin or an ascomycin, e.g. Cyclosporin A (NEORAL®), FK506 (tacrolimus), pimecrolimus, a mTOR inhibitor, e.g. rapamycin or a derivative thereof, e.g. Sirolimus (RAPAMUNE®), Everolimus (Certican®), temsirolimus, zotarolimus, biolimus-7, biolimus-9, a rapalog, e.g.ridaforolimus, azathioprine, campath 1H, a SIP receptor modulator, e.g. fingolimod or an analogue thereof, an anti IL-8 antibody, mycophenolic acid or a salt thereof, e.g. sodium salt, or a prodrug thereof, e g. Mycophenolate Mofetil (CELLCEPT®), OKT3 (ORTHOCLONE OKT3®), Prednisone, ATGAM®, THYMOGLOBULIN®, Brequinar Sodium, OKT4, T10B9. A-3A, 33B3.1, 15-deoxyspergualin, tresperimus, Leflunomide ARAVA®, CTLAI-Ig, anti-CD25, anti-IL2R, Basiliximab (SIMULECT®), Daclizumab (ZENAPAX®), mizorbine, methotrexate, dexamethasone, ISAtx-247, SDZ ASM 981 (pimecrolimus, Elidel®), CTLA41g (Abatacept), belatacept, LFA31g„ etanercept (sold as Enbrel® by Immunex), adalimumab (Humira®), infliximab (Remicade®), an anti-LFA-1 antibody, natalizumab (Antegren®), Enlimomab, gavilimomab, antithymocyte immunoglobulin, siplizumab, Alefacept efalizumab, pentasa, mesalazine, asacol, codeine phosphate, benorylate, fenbufen, naprosyn, diclofenac, etodolac and indomethacin, aspirin and ibuprofen.

[0270] In some embodiments, the bioactive agent is a therapeutic agent which is a biologic such a cytokine (e.g., interferon or an interleukin (e.g., IL-2)) used in cancer treatment. In some embodiments the biologic is an anti -angiogenic agent, such as an anti-VEGF agent, e.g., bevacizumab (AVASTIN®). In some embodiments the biologic is an immunoglobulin-based biologic, e.g., a monoclonal antibody (e.g., a humanized antibody, a fully human antibody, an Fc fusion protein or a functional fragment thereof) that agonizes a target to stimulate an anti-cancer response, or antagonizes an antigen important for cancer. Such agents include RITUXAN® (rituximab); ZENAPAX® (daclizumab); SIMULECT® (basiliximab); SYNAGIS® (palivizumab); REMICADE® (infliximab); HERCEPTIN® (trastuzumab);MYLOTARG® (gemtuzumab ozogamicin); CAMPATH® (alemtuzumab);ZEVALIN® (ibritumomab tiuxetan); HUMIRA® (adalimumab); XOLAIR® (omalizumab); BEXXAR® (tositumomab-1- 131 ); RAPTIVA® (efalizumab);ERBITUX® (cetuximab); AVASTIN® (bevacizumab); TYSABRI® (natalizumab); ACTEMRA® (tocilizumab); VECTIBIX® (panitumumab); LUCENTIS®P25-212-PRI-US01(ranibizumab); SOLIRIS® (eculizumab); CIMZIA® (certolizumab pegol);SIMPONI® (golimumab); ILARIS® (canakinumab); STELARA® (ustekinumab); ARZERRA® (ofatumumab); PROLIA® (denosumab); NUMAX® (motavizumab); ABTHRAX® (raxibacumab); BENLYSTA® (belimumab); YERVOY® (ipilimumab); ADCETRIS® (brentuximab vedotin); PERJETA® (pertuzumab); KADCYLA® (ado- trastuzumab emtansine); and GAZYVA® (obinutuzumab). Also included are antibody-drug conjugates.

[0271] The combination therapy may include a therapeutic agent which is a non-drug treatment. For example, the compound could be administered in addition to radiation therapy, cryotherapy, hyperthermia, and / or surgical excision of tumor tissue.

[0272] In certain embodiments the first and second therapeutic agents are administered simultaneously or sequentially, in either order. The first therapeutic agent may be administered immediately, up to 1 hour, up to 2 hours, up to 3 hours, up to 4 hours, up to 5 hours, up to 6 hours, up to 7 hours, up to, 8 hours, up to 9 hours, up to 10 hours, up to 11 hours, up to 12 hours, up to 13 hours, 14 hours, up to hours 16, up to 17 hours, up 18 hours, up to 19 hours up to 20 hours, up to 21 hours, up to 22 hours, up to 23 hours up to 24 hours or up to 1-7, 1-14, 1-21 or 1-30 days before or after the second therapeutic agent.

[0273] In certain embodiments the second therapeutic agent is administered on a different dosage schedule than the compound of the present invention. For example the second therapeutic agent may have a treatment holiday of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days per treatment cycle. In another embodiment the first therapeutic agent has a treatment holiday. For example the first therapeutic agent may have a treatment holiday of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days per treatment cycle. In certain embodiments both the first and second therapeutic have a treatment holiday.PHARMACEUTICAL COMPOSITIONS

[0274] A compound of the present invention or a pharmaceutically acceptable salt thereof can be used as a therapeutically active substance, e.g. in the form of a pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatinP25-212-PRI-US01capsules, solutions, emulsions or suspensions. In other embodiments the compound is administered paternally, for example by intravaneous administration. In other embodiments the pharmaceutical composition is administered rectally, e.g. in the form of suppositories.

[0275] A compound of the present invention or a pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatin capsules. Suitable carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatin capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

[0276] The pharmaceutical preparations can, moreover, contain pharmaceutically acceptable auxiliary substances such as preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

[0277] Medicaments containing a compound of the present invention or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also provided by the present invention, as is a process for their production, which comprises bringing one or more compounds of the present invention and / or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.

[0278] The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of the present invention or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered asP25-212-PRI-US01single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.

[0279] In certain embodiments the pharmaceutical composition is in a dosage form that contains from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of the active compound and optionally from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of an additional active agent in a unit dosage form. Examples are dosage forms with at least 0.1, 1, 5, 10, 25, 50, 100, 200, 250, 300, 400, 500, 600, 700, or 750 mg of active compound, or its salt.

[0280] In some embodiments, compounds disclosed herein or used as described are administered once a day (QD), twice a day (BID), or three times a day (TID). In some embodiments, compounds disclosed herein or used as described are administered at least once a day for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, at least 22 days, at least 23 days, at least 24 days, at least 25 days, at least 26 days, at least 27 days, at least 28 days, at least 29 days, at least 30 days, at least 31 days, at least 35 days, at least 45 days, at least 60 days, at least 75 days, at least 90 days, at least 120 days, at least 150 days, at least 180 days, or longer.

[0281] In certain embodiments the compound of the present invention is administered once a day, twice a day, three times a day, or four times a day.

[0282] In certain embodiments the compound of the present invention is administered orally once a day. In certain embodiments the compound of the present invention is administered orally twice a day. In certain embodiments the compound of the present invention is administered orally three times a day. In certain embodiments the compound of the present invention is administered orally four times a day.

[0283] In certain embodiments the compound of the present invention is administered intravenously once a day. In certain embodiments the compound of the present invention is administered intravenously twice a day. In certain embodiments the compound of the present invention is administered intravenously three times a day. In certain embodiments the compound of the present invention is administered intravenously four times a day.P25-212-PRI-US01

[0284] In some embodiments the compound of the present invention is administered with a treatment holiday in between treatment cycles. For example the compound may have a treatment holiday of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days per treatment cycle.

[0285] In some embodiments a loading dose is administered to begin treatment. For example, the compound may be administered about 1.5x, about 2x, about 2.5x, about 3x, about 3.5x, about 4x, about 4.5x, about 5x, about 5.5x, about 6x, about 6.5x, about 7x, about 7.5x, about 8x, about 8.5x, about 9x, about 9.5x, or about lOx higher dose on the first day of treatment than the remaining days of treatment in the treatment cycle. Additional exemplary loading doses include about 1.5x, about 2x, about 2.5x, about 3x, about 3.5x, about 4x, about 4.5x, about 5x, about 5.5x, about 6x, about 6.5x, about 7x, about 7.5x, about 8x, about 8.5x, about 9x, about 9.5x, or about lOx higher dose on the first 2, 3, 4, 5, 6, 7, 8, 9, or 10 days of treatment than the remaining days of treatment in the treatment cycle.

[0286] The pharmaceutical composition may also include a molar ratio of the active compound and an additional active agent. For example the pharmaceutical composition may contain a molar ratio of about 0.5:1, about 1:1, about 2:1, about 3:1 or from about 1.5:1 to about 4:1 of an anti-inflammatory or immunosuppressing agent.

[0287] These compositions can contain any amount of active compound that achieves the desired result, for example between 0.1 and 99 weight % (wt. %) of the compound and usually at least about 5 wt. % of the compound. Some embodiments contain from about 25 wt. % to about 50 wt. % or from about 5 wt. % to about 75 wt. % of the compound.

[0288] A pharmaceutically or therapeutically effective amount of the composition will be delivered to the patient. The precise effective amount will vary from patient to patient, and will depend upon the species, age, the subject’s size and health, the nature and extent of the condition being treated, recommendations of the treating physician, and the therapeutics or combination of therapeutics selected for administration. The effective amount for a given situation can be determined by routine experimentation. For purposes of the disclosure, a therapeutic amount may for example be in the range of about 0.01 mg / kg to about 250 mg / kg body weight, more typically about 0.1 mg / kg to about 10 mg / kg, in at least one dose. The subject can be administered as many doses as is required to reduce and / or alleviate the signs, symptoms, or causes of theP25-212-PRI-US01disorder in question, or bring about any other desired alteration of a biological system. When desired, formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient.

[0289] In certain embodiments the dose ranges from about 0.01-100 mg / kg of patient bodyweight, for example about 0.01 mg / kg, about 0.05 mg / kg, about 0.1 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 1.5 mg / kg, about 2 mg / kg, about 2.5 mg / kg, about 3 mg / kg, about 3.5 mg / kg, about 4 mg / kg, about 4.5 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, about 50 mg / kg, about 55 mg / kg, about 60 mg / kg, about 65 mg / kg, about 70 mg / kg, about 75 mg / kg, about 80 mg / kg, about 85 mg / kg, about 90 mg / kg, about 95 mg / kg, or about 100 mg / kg.

[0290] The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packed tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

[0291] In certain embodiments the compound is administered as a pharmaceutically acceptable salt. Non-limiting examples of pharmaceutically acceptable salts include: acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, di gluconate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3 -phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, and valerate salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine.P25-212-PRI-US01

[0292] Thus, the composition of the disclosure can be administered as a pharmaceutical formulation including one suitable for oral (including buccal and sublingual), rectal, nasal, topical, transdermal, pulmonary, vaginal or parenteral (including intramuscular, intra-arterial, intrathecal, subcutaneous and intravenous), injections, inhalation or spray, intra-aortal, intracranial, subdermal, intraperitioneal, subcutaneous, or by other means of administration containing conventional pharmaceutically acceptable carriers. A typical manner of administration is oral, topical or intravenous, using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.

[0293] Depending on the intended mode of administration, the pharmaceutical compositions can be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, syrup, suspensions, creams, ointments, lotions, paste, gel, spray, aerosol, foam, or oil, injection or infusion solution, a transdermal patch, a subcutaneous patch, an inhalation formulation, in a medical device, suppository, buccal, or sublingual formulation, parenteral formulation, or an ophthalmic solution, or the like, preferably in unit dosage form suitable for single administration of a precise dosage.

[0294] Some dosage forms, such as tablets and capsules, are subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose. The compositions will include an effective amount of the selected drug in combination with a pharmaceutically acceptable carrier and, in addition, can include other pharmaceutical agents, adjuvants, diluents, buffers, and the like.

[0295] Carriers include excipients and diluents and must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated. The carrier can be inert or it can possess pharmaceutical benefits of its own. The amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.

[0296] Classes of carriers include, but are not limited to adjuvants, binders, buffering agents, coloring agents, diluents, disintegrants, excipients, emulsifiers, flavorants, gels, glidents, lubricants, preservatives, stabilizers, surfactants, solubilizer, tableting agents, wetting agents or solidifying material.P25-212-PRI-US01

[0297] Some carriers may be listed in more than one class, for example vegetable oil may be used as a lubricant in some formulations and a diluent in others.

[0298] Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin; talc, petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers and vegetable oils. Optional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of the present invention.

[0299] Some excipients include, but are not limited, to liquids such as water, saline, glycerol, polyethylene glycol, hyaluronic acid, ethanol, and the like. The compound can be provided, for example, in the form of a solid, a liquid, spray dried material, a microparticle, nanoparticle, controlled release system, etc., as desired according to the goal of the therapy. Suitable excipients for non-liquid formulations are also known to those of skill in the art. A thorough discussion of pharmaceutically acceptable excipients and salts is available in Remington’s Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990).

[0300] Additionally, auxiliary substances, such as wetting or emulsifying agents, biological buffering substances, surfactants, and the like, can be present in such vehicles. A biological buffer can be any solution which is pharmacologically acceptable, and which provides the formulation with the desired pH, i.e., a pH in the physiologically acceptable range. Examples of buffer solutions include saline, phosphate buffered saline, Tris buffered saline, Hank’s buffered saline, and the like.

[0301] For solid compositions, conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, and the like, an active compound as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered can also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and the like. Actual methods of preparing such dosage forms are known, or will be apparent,P25-212-PRI-US01to those skilled in this art; for example, see Remington’s Pharmaceutical Sciences, referenced above.

[0302] In yet another embodiment provided is the use of permeation enhancer excipients including polymers such as: poly cations (chitosan and its quaternary ammonium derivatives, poly-L-arginine, aminated gelatin); polyanions (N-carboxymethyl chitosan, poly-acrylic acid); and, thiolated polymers (carboxymethyl cellulose-cysteine, polycarbophil-cysteine, chitosan-thiobutylamidine, chitosan-thioglycolic acid, chitosan-glutathione conjugates).

[0303] In certain embodiments the excipient is selected from butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

[0304] The pharmaceutical compositions / combinations can be formulated for oral administration. For oral administration, the composition will generally take the form of a tablet, capsule, a softgel capsule or can be an aqueous or nonaqueous solution, suspension or syrup. Tablets and capsules are typical oral administration forms.Tablets and capsules for oral use can include one or more commonly used carriers such as lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. Typically, the compositions of the disclosure can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, com sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodiumP25-212-PRI-US01chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

[0305] When liquid suspensions are used, the active agent can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like and with emulsifying and suspending agents. If desired, flavoring, coloring and / or sweetening agents can be added as well. Other optional components for incorporation into an oral formulation herein include, but are not limited to, preservatives, suspending agents, thickening agents, and the like.

[0306] For ocular delivery, the compound can be administered, as desired, for example, via intravitreal, intrastromal, intracameral, sub-tenon, sub-retinal, retrobulbar, peribulbar, suprachorodial, conjunctival, subconjunctival, episcleral, periocular, transscleral, retrobulbar, posterior juxtascleral, circumcorneal, or tear duct injections, or through a mucus, mucin, or a mucosal barrier, in an immediate or controlled release fashion or via an ocular device.

[0307] Parenteral formulations can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solubilization or suspension in liquid prior to injection, or as emulsions. Typically, sterile injectable suspensions are formulated according to techniques known in the art using suitable carriers, dispersing or wetting agents and suspending agents. The sterile injectable formulation can also be a sterile injectable solution or a suspension in a acceptably nontoxic parenterally acceptable diluent or solvent. Among the acceptable vehicles and solvents that can be employed are water, Ringer’s solution and isotonic sodium chloride solution. In addition, sterile, fixed oils, fatty esters or polyols are conventionally employed as solvents or suspending media. In addition, parenteral administration can involve the use of a slow release or sustained release system such that a constant level of dosage is maintained.

[0308] Parenteral administration includes intraarticular, intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, and include aqueous and nonaqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. Administration via certain parenteral routes can involve introducing the formulations of the disclosure into the body of a patient through a needle or a catheter, propelled byP25-212-PRI-US01a sterile syringe or some other mechanical device such as a continuous infusion system. A formulation provided by the disclosure can be administered using a syringe, injector, pump, or any other device recognized in the art for parenteral administration.

[0309] Preparations according to the disclosure for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms can also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They can be sterilized by, for example, filtration through a bacteria retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured using sterile water, or some other sterile injectable medium, immediately before use.

[0310] Sterile injectable solutions are prepared by incorporating one or more of the compounds of the disclosure in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, typical methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. Thus, for example, a parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized.

[0311] Alternatively, the pharmaceutical compositions of the disclosure can be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable nonirritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

[0312] The pharmaceutical compositions of the disclosure can also be administered by nasal aerosol or inhalation. Such compositions are prepared according toP25-212-PRI-US01techniques well-known in the art of pharmaceutical formulation and can be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, propellants such as fluorocarbons or nitrogen, and / or other conventional solubilizing or dispersing agents.

[0313] Formulations for buccal administration include tablets, lozenges, gels and the like. Alternatively, buccal administration can be effected using a transmucosal delivery system as known to those skilled in the art. The compounds of the disclosure can also be delivered through the skin or muscosal tissue using conventional transdermal drug delivery systems, i.e., transdermal “patches” wherein the agent is typically contained within a laminated structure that serves as a drug delivery device to be affixed to the body surface. In such a structure, the drug composition is typically contained in a layer, or “reservoir,” underlying an upper backing layer. The laminated device can contain a single reservoir, or it can contain multiple reservoirs. In certain embodiments, the reservoir comprises a polymeric matrix of a pharmaceutically acceptable contact adhesive material that serves to affix the system to the skin during drug delivery. Examples of suitable skin contact adhesive materials include, but are not limited to, polyethylenes, polysiloxanes, polyisobutylenes, polyacrylates, polyurethanes, and the like.

[0314] Formulations suitable for administration to the lungs can be delivered by a wide range of passive breath driven and active power driven single / -multiple dose dry powder inhalers (DPI). The devices most commonly used for respiratory delivery include nebulizers, metered-dose inhalers, and dry powder inhalers. Several types of nebulizers are available, including jet nebulizers, ultrasonic nebulizers, and vibrating mesh nebulizers. Selection of a suitable lung delivery device depends on parameters, such as nature of the drug and its formulation, the site of action, and pathophysiology of the lung.

[0315] In certain embodiments an oral formulation is provided.SYNTHETIC METHODS

[0316] The compounds of the present invention may contain one or more asymmetric centers and can therefore occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it isP25-212-PRI-US01intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within this invention. The present invention is meant to encompass all such isomeric forms of these compounds. The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration. If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography.

[0317] In the embodiments, where optically pure enantiomers are provided, optically pure enantiomer means that the compound contains > 90 % of the desired isomer by weight, particularly > 95 % of the desired isomer by weight, or more particularly > 99 % of the desired isomer by weight, said weight percent based upon the total weight of the isomer(s) of the compound. Chirally pure or chirally enriched compounds may be prepared by chirally selective synthesis or by separation of enantiomers. The separation of enantiomers may be carried out on the final product or alternatively on a suitable intermediate.Isolation and purification of the compounds

[0318] Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the preparations and examples herein below. However, other equivalent separation or isolation procedures could, of course, also be used. Racemic mixtures of chiral compounds of the present invention can be separated using chiral HPLC. Racemic mixtures of chiral synthetic intermediates may also be separated using chiral HPLC.P25-212-PRI-US01Salts of compounds of the present invention

[0319] In cases where the compound of the present invention is basic they may be converted to a corresponding acid addition salt. The conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. A specific salt is the fumarate. Typically, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent. The temperature is maintained between 0 °C and 50 °C. The resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.

[0320] Insofar as their preparation is not described in the examples, compounds of the present invention as well as intermediate products can be prepared according to analogous methods or according to the methods set forth herein. Starting materials are commercially available, known in the art or can be prepared by methods known in the art or in analogy thereto.

[0321] It will be appreciated that the compounds of the present invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.NMR Spectra

[0322] NMR Spectra were acquired on a VarianUnityInova or Bruker 400 MHz NMR spectrometer equipped with an Automation Triple Broadband (ATB) probe. The ATB probe was simultaneously tuned to1H,19F and13C. For typical 'H NMR spectra, the pulse angle was 45 degrees, 8 scans were summed, and the spectral width was 16 ppm (-2 ppm to 14 ppm). A total of 32768 complex points was collected during the 5.1 second acquisition time, and the recycle delay was set to 1 second. Spectra were collected at 25°C.1H NMR Spectra are typically processed with 0.2 Hz line broadening and zero-filling to 131072 points prior to Fourier transformation.P25-212-PRI-US01Preparative HPLC

[0323] Preparative HPLC was performed using either a Waters Atlantis dC18OBD 10 μM (30x250 mm) column or a Waters Sunfire Prep C18OBD 10 μM (30x250 mm) column. The columns were used at a flow rate of 60 ml / min on a Waters Prep LC 4000 System equipped with a sample loop (10 ml) and an ISCO UA-6 UV / Vis detector. The mobile phase was drawn from two solvent reservoirs containing (A) water and (B) HPLC-grade acetonitrile. A typical preparative run used a linear gradient (e.g., 0-60% solvent B over 60 min).P25-212-PRI-US01LC-MS methodsP25-212-PRI-US01P25-212-PRI-US01GENERAL SYNTHESIS

[0324] List of intermediates which can be obtained according to the reference or general procedure (GP) and starting materials (CAS# are commercially available).Step 1:

[0325] A mixture of 3-amino-6-bromopyrazine-2-carbaldehyde (10 g; 47 mmol; 1 eq.) and (17?,25)-l-amino-2, 3 -dihydro- lH-inden-2-ol (7.4 g; 47.1 mmol; 1.0 eq.) in DCE (300 ml) was stirred for 30 min at room temperature under nitrogen atmosphere.To the above mixture was added sodium triacetoxyborohydride (31.5 g; 141.2 mmol;3.0 eq.) at 0 °C. Then the resulting mixture was stirred for additional 2 h at room temperature.

[0326] The reaction was quenched by the addition of Water (100 ml) at room temperature. The resulting mixture was extracted with DCM (3x100 ml). Thecombined organic layers were washed with water (2x100 ml), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with DCM / MeOH (10:1) to afford (17?,25)-l-{[(3-amino-6-bromopyrazin-2-yl) methyl]amino}-2,3- dihydro-lH-inden-2-ol (12.0 g; 35.5 mmol; 76%) as a yellow solid.P25-212-PRI-US01Step 2:

[0327] To a stirred mixture of (lA,2S)-l-{[(3-amino-6-bromopyrazin-2-yl)methyl]amino}-2,3-dihydro-lH-inden-2-ol (12 g; 35.5 mmol; 1.0 eq.) and (triethoxymethoxy)ethane (15.0 ml; 68.1 mmol; 1.9 eq.) in MeCN (120 ml) was added acetic acid (8.3 ml; 137.6 mmol; 3.9 eq.) at room temperature. The resulting mixture was stirred for 2 h at 60 °C under nitrogen atmosphere.

[0328] The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with DCMZEtOAc (1: 1) to afford (2A,10S)-17-bromo-ll-oxa-l,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3,5,7,12,14(19),15,17-heptaene (8.0 g; 18.4 mmol; 52%) as a yellow solid.Step 3:

[0329] 2R, 1 OS)- 17 -bromo- 11 -oxa- 1,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3,5,7,12,14(19),15,17-heptaene (93 mg) was dissolved in DMF (1.8 ml). 4-Ethynyl-N-methylaniline (65 mg), triethylamine (262 pl), copper(I) iodide (5 mg) and bis(triphenylphosphine) palladium(II) chloride (9 mg) were added. The reaction mixture was flushed with argon and stirred at 80 °C for 2 hours.

[0330] The dark brown reaction mixture was poured into approx. 20 ml ammonium chloride solution and stirred Ihr at room temperature. The precipitate was filtered off by suction, washed with water and dried to yield 131 mg beige solid.

[0331] The crude product was purified by flash chromatography eluted with c-hex / EtOAc (10:90)

[0332] to yield N-methyl-4- {2-[(2A, 1 OS)- 11 -oxa- 1,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]-icosa-3,5,7,12,14(19),15,17-heptaen-17-yl]ethynyl}aniline (73 mg; 0.19 mmol) as yellow solid.P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01Step 1:

[0333] To a stirred mixture of 3-amino-6-bromopyrazine-2-carbaldehyde (2.2 g, 10.3 mmol, 1.0 equiv, 95%), 5-ethynyl-l-methyl-3-(trifluoromethyl)pyrazole (2.9 g, 16.4 mmol, 1.6 equiv), Cui (0.2 g, 1.0 mmol, 0.1 equiv, 95%) and TEA (30 ml, 205 mmol,20 equiv, 95%) in THF (30 ml, 370 mmol, 36 equiv, 100%) were added Dppf (0.6 g,1.0 mmol, 0.1 equiv, 95%) and Dppf palladium(II) biphenyl-2-amine (1.0 g, 1.0mmol, 0.1 equiv, 95%) at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 2 h at 80 °C under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gelcolumn chromatography, eluted with PEZEtOAc (3:1) to afford 3-amino-6-[2-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]ethynyl]pyrazine-2-carbaldehyde (1.95 g,63%) as a yellow solid.Step 2:

[0334] rac-(lR,2S)-l-amino-6-methoxy-2,3-dihydro-lH-inden-2-ol (919 mg) and 3-amino-6-{2-[ l-methyl-3-(tri fluoromethyl)- lH-pyrazol-5-yl]ethynyl }pyrazine-2-carbaldehyde (1103 mg) were suspended in 1,2-di chloroethane (30 ml) and stirred for2.5 hrs at room temperature. Brown solution. Sodium triacetoxyborohydride (3863P25-212-PRI-US01mg) was added and the mixture was stirred Ihr at room temperature. Brown turbid solution.

[0335] The reaction mixture was diluted with dichlormethane and extracted with water. The organic phase was extracted with sat. sodium hydrogencarbonate solution, then dried with sodium sulfate, filtered and the solvent evaporated under reduced pressure to yield 1,57g brown solid.

[0336] The crude product was purified twice by flash chromatography

[0337] to yield rac-(lA,25)-l-{[(3-amino-6-{2-[l-methyl-3-(trifhioromethyl)-lH-pyrazol-5-yl]ethynyl}pyrazin-2-yl)methyl]amino}-6-methoxy-2,3-dihydro-lH-inden-2-ol (768 mg; 1.39 mmol) as a beige solid.

[0338] Step 3:

[0339] rac-( \R, 2S)~ 1 - { [(3 -amino-6- { 2-[ 1 -methyl-3 -(trifluoromethyl)- 1 H-pyrazol-5-yl]ethynyl}pyrazin-2-yl)methyl]amino}-6-methoxy-2,3-dihydro-lH-inden-2-ol (200 mg) was suspended in acetonitrile (4 ml). Tetraethyl orthocarbonate (230 pl) and acetic acid (glacial) (104 pl) were added, and the mixture was stirred 5.5 hrs at 60 °C.

[0340] The reaction mixture was treated with water. The precipitate was filtered off by suction, washed with water and dried to yield rac-(2A,105)-5-methoxy-17-{2-[l-methyl-3 -(trifluoromethyl)- lH-pyrazol-5-yl]ethynyl } - 11 -oxa- 1,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3,5,7,12,14,16,18-heptaene (126 mg; 0.27 mmol) as beige solid.

[0341] The following compounds were prepared as described for example compound Bl above.P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01Step 1:

[0342] A mixture of (2R,10S)-17-bromo-11-oxa-1,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]-icosa-3,5,7,12,14(19),15,17-heptaene (1.0 g;2.34 mmol; 1.0 eq.), tert-butyl (4-ethynyl-3-methylphenyl)(methyl)carbamate (1.76 g;7.2 mmol; 3.0 eq.), Cui (239 mg; 1.2 mmol; 0.5 eq.), dppf (69 mg; 0.1 mmol; 0.05eq.), Dppf Pd G3 (0.12 g; 0.12 mmol; 0.05 eq.) and TEA (1.27 ml; 4.78 mmol; 2.0eq.) in THF (20 ml) was stirred for 2 h at 80 °C under nitrogen atmosphere.

[0343] The resulting mixture was concentrated under reduced pressure. The residuewas purified by silica gel column chromatography, eluted with DCM / MeOH (15:1) to afford tert-butyl N-methyl-N-(3-methyl-4-{2-[(2R,10S)-11-oxa-1,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18-heptaen-17-yl]ethynyl}phenyl)carbamate (1.00 g; 1.94 mmol; 81%; yellow solid).Step 2:

[0344] A mixture of tert-butyl N-methyl-N-(3-methyl-4-{2-[(2R,10S)-11-oxa-1,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18-heptaen-17-yl]ethynyl}phenyl)carbamate (1.70 g; 3.21 mmol; 1.0 eq.) in 4M HCl in MeOH (20 ml; 80 mmol; 25 eq.) was stirred for 1 h at room temperature undernitrogen atmosphere.

[0345] The mixture was basified to pH 8 with saturated NaHCO3(aq.). The resulting mixture was extracted with EtOAc (3x30 ml), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue wasP25-212-PRI-US01purified by silica gel column chromatography, eluted with DCM / MeOH (10: 1) to afford N,3-dimethyl-4-{2-[(2R,10S)-11-oxa-1,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18-heptaen-17-yl]ethynyl}aniline (400 mg; 0.95 mmol; 29%; yellow solid).Step 3:

[0346] To a stirred mixture of N,3-dimethyl-4-{2-[(2R,10S)-11-oxa-1,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18-heptaen-17-yl]ethynyl}aniline (100 mg; 0.11 mmol; 1.0 eq.) and TEA (0.10 ml; 0.66 mmol; 5.9 eq.) in DCM (3 ml) was added prop-2-enoyl chloride (0.06 ml; 0.70 mmol; 6.3 eq.) at 0 °C. The resulting mixture was stirred for 2 h at room temperature under nitrogen atmosphere.

[0347] The reaction was quenched by addition of 20 ml water at room temperature. The resulting mixture was extracted with DCM (3 x 20 ml) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC (Column: XBridge Prep OBD Cl 8 Column, 30* 150mm 5um; Mobile Phase A: Water (lOmmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate:60 ml / min; Gradient:25% B to 55% B in 9 min; 254 nm; RT: 7min) to afford N-methyl-N-(3-methyl-4-{2-[(2R,10S)-11-oxa-1,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18-heptaen-17-yl]ethynyl}phenyl)prop-2-enamide (23 mg; 0.05 mmol; 45%; yellow solid)P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01Step 1:

[0348] (2R,10S)-17-bromo-11-oxa-1,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18-heptaene (93 mg) was dissolved in DMF (1.9 ml). 4-Ethynyl-N-methylaniline (65 mg), triethylamine(2623 pl), copper(I) iodide (5 mg) and bis(triphenylphosphine)palladium(II) chloride(9 mg) were added. The reaction mixture was flushed with argon and stirred at 80 °Cfor 2 hours.

[0349] The dark brown reaction mixture was poured into approx. 20ml ammoniumchloride solution and stirred Ihr at room temperature. Brown suspension. TheP25-212-PRI-US01precipitate was filtered off by suction, washed with water and dried to yield 131 mg beige solid.

[0350] The crude product was purified by flash chromatography

[0351] to yield N-methyl-4- {2-[(2R, 1 OS)- 11 -oxa- 1,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18-heptaen-17-yl]ethynyl}aniline (73 mg; 0.19 mmol; 69%) as yellow solid.Step 2:

[0352] N-methyl-4- {2-[(2R, 1 OS)- 11 -oxa- 1,13,15,18-tetraazapentacyclo-[10.8.0.02,10.03,8.014,19]-icosa-3(8),4,6,12,14,16,18-heptaen-17-yl]ethynyl}aniline (34 mg) and acryloyl chloride 97.0%, (8 pl) were dissolved in dichloromethane (1 ml), triethylamine (14 pl) was added and the mixture was stirred for 2 hrs at room temperature.

[0353] The reaction mixture was directly purified twice by flash chromatography

[0354] to yield N-methyl-N-(4-{2-[(27?, 1 OS)- 11 -oxa- 1,13,15,18-tetraazapentacyclo [10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18-heptaen-17-yl]ethynyl}phenyl)prop-2-enamide (15 mg; 0,029 mmol; 35%) as yellow solid.P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01

[0355] Pro = amino protecting groupStep 1:

[0356] To a stirred solution of 4-bromo-2-methylphenol (10.0 g; 50.8 mmol; 1.0 eq.), tert-butyl 3 -(hydroxymethyl)pyrrolidine-l -carboxylate (10.8 g; 50.8 mmol; 1.0 eq.)and PPh3(17.5 g; 63.5 mmol; 1.3 eq.) in THF (200 ml) was added DEAD (11.6 g;P25-212-PRI-US0163.5 mmol; 1.3 eq.) dropwise at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for overnight at room temperature under nitrogen atmosphere.

[0357] The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EtOAc (10:1) to afford tert-butyl 3-[(4-bromo-2-methylphenoxy)methyl]pyrrolidine-l-carboxylate (14.0 g; 26.4 mmol; 52%; yellow oil).Step 2:

[0358] A mixture of tert-butyl 3-[(4-bromo-2-methylphenoxy)methyl]pyrrolidine-l-carboxylate (14.0 g; 28.2 mmol; 1.0 eq.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (9.0 g; 33.8 mmol; 1.2 eq.), KOAc (5.8 g; 56.3 mmol; 2.0 eq.), Dppf (0.82 g; 1.4 mmol; 0.05 eq.) and Pd(dppf)C12 (1.0 g; 1.4 mmol; 0.05 eq.) in Dioxane-1,4 (175 ml) was stirred for overnight at 100 °C under nitrogen atmosphere.

[0359] The reaction was quenched by the addition of Water (100 ml) at room temperature. The resulting mixture was extracted with DCM (3x60 ml). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EtOAc (8:2) to afford tert-butyl 3-{[2-methyl-4-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)phenoxy]methyl (pyrrolidine-1-carboxylate (12.9 g; 23.4 mmol; 83%; yellow oil).Step 3:

[0360] A mixture of tert-butyl 3-{[2-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy]methyl}pyrrolidine-l-carboxylate (1.3 g; 2.5 mmol; 1.4 eq.), (2A,105)-17-bromo-ll-oxa-l,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18-heptaene (700 mg; 1.7 mmol; 1.0 eq.), Pd(PPh3)4(238 mg; 0.2 mmol; 0.1 eq.) and K2CO3(566 mg; 3.9 mmol; 2.2 eq.) in dioxane (15 ml) and H2O (3 ml) was stirred for 4 h at 100 °C under N2 atmosphere.

[0361] The mixture was allowed to cool down to room temperature. The resulting mixture was extracted with DCM (3x60 ml). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with DCM / MeOH (10:1) to afford tert-butyl 3-({2-methyl-4-[(2A,105)-l 1 -oxa- 1,13,15,18-P25-212-PRI-US01tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18-heptaen-17-yl]phenoxy}methyl)pyrrolidine-l-carboxylate (1.1 g; 1.6 mmol; 91%).Step 4:

[0362] A solution of tert-butyl 3-({2-methyl-4-[(2A,105)-l l-oxa-1,13,15,18-tetraazapentacyclo [10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18-heptaen-17-yl]phenoxy}methyl)pyrrolidine-l-carboxylate (1.1 g; 1.6 mmol; 1.0 eq.) and TFA (8 ml) in DCM (40 ml) was stirred for 1 h at room temperature.

[0363] The solution was neutralized to pH 7 with saturated NaHCO3(aq.). The resulting mixture was extracted with DCM (3x60 ml). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with DCM / MeOH (5:1) to afford (2A,105)-17-{3-methyl-4-[(pyrrolidin-3 -yl)m ethoxy ]phenyl } - 11 -oxa- 1,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18-heptaene (724 mg; 1.6 mmol; 99%; white solid).Step 5:

[0364] A solution of (2A,105)-17-{3-methyl-4-[(pyrrolidin-3-yl)methoxy]phenyl}- 1 l-oxa-l,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18-heptaene (724 mg; 1.59 mmol; 1.0 eq.), prop-2-enoyl chloride (288 mg; 3.0 mmol; 1.9 eq.) and TEA (485 mg; 4.5 mmol; 2.9 eq.) in DCM (10 ml) was stirred for 1 h at room temperature.

[0365] The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-TLC ([DCM / MeOH] [20:1]) to afford l-[3-({2-methyl-4-[(2A,105)-l 1 -oxa- 1,13, 15,18-tetraazapentacyclo[l 0.8.0.02,10.03,8.014,19]icosa- 3 (8), 4, 6, 12,14,16,18-heptaen- 17-yl]phenoxy }methyl)pyrrolidin- 1 -yl]prop-2-en- 1 -one.P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01Step 1:

[0366] A solution of 3-[(4-bromo-2-methylphenoxy)methyl]-3-methyloxetane (1.9 g;6.7 mmol; 1.0 eq.), Bis(pinacolato)diboron (2.1 g; 8.0 mmol; 1.2 eq.),Pd(dppf)C12. DCM (0.3 g; 0.3 mmol; 0.05 eq.), dppf (0.2 g; 0.3 mmol; 0.05 eq.),KOAc (1.4 g; 13.4 mmol; 2.0 eq.) was dissolved in dioxane (15 ml) at roomtemperature. The resulting mixture was stirred for 2 h at 100 °C under N2 atmosphere.

[0367] The resulting mixture was diluted with water and extracted with EtOAc (5x100ml). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue waspurified by silica gel column chromatography, eluted with PE / EtOAc (10: 1) to afford 4,4,5,5-tetramethyl-2-{3-methyl-4-[(3-methyloxetan-3-yl)methoxy]phenyl}-l,3,2- dioxaborolane (1.2 g; 3.7 mmol; 55%; yellow oil).Step 2:

[0368] To a 4,4,5,5-tetramethyl-2-{3-methyl-4-[(3-methyloxetan-3- yl)methoxy]phenyl}-l,3,2-dioxaborolane (400 mg; 1.3 mmol; 1.0 eq.) and (2R,10S)- 17-bromo-l 1-oxa-l, 13, 15,18-tetraazapentacyclo[l 0.8.0.02,10.03,8.014,19]icosa- 3(8),4,6,12,14,16,18-heptaene (215 mg; 0.6 mmol; 0.5 eq.) in dioxane (8 ml) andwater (8 ml) were added Pd(dppf)Cl2(45 mg; 0.1 mmol; 0.05 eq.), K2CO3(347 mg;2.5 mmol; 2.0 eq.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 2 h at 100 °C under nitrogen atmosphere.

[0369] The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with DCM / MeOH (10:1) yielding

[0370] (2R, 10 S)- 17- { 3 -methyl-4- [(3 -methyloxetan-3 -yl)methoxy ]phenyl } - 11 -oxa- l,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19]icosa-3(8),4,6,12,14,16,18- heptaene (57 mg; 0.1 mmol; 10%; white solid)P25-212-PRI-US01P25-212-PRI-US01Step 1:

[0371] A mixture of (2R,10S)-17-bromo-11-oxa-1,13,15,18-tetraazapentacyclo[10.8.0.02,10.03,8.014,19] icosa-3(8),4,6,12,14,16,18-heptaene (1.0 g;2.3 mmol; 1.0 eq.) and (4-bromo-3-methylphenyl)boronic acid (519 mg; 2.3 mmol;1.0 eq.) and K2CO3(666 mg; 4.6 mmol; 2.0 eq.) and Pd(dppf)C12 (88 mg; 0.1 mmol;0.05 eq.) in dioxane (36 ml) and water (4.5 ml) was stirred for 2 h at 100 °C under nitrogen atmosphere.

[0372] The resulting mixture was concentrated under vacuum. The residue waspurified by reverse flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN / water, 40% to 70% gradient in 20 min; detector, UV254 nm; to afford (2A,105)-17-(3-methyl-4-{2-oxa-6-azaspiro[3.4]octan-6- yl}phenyl)-l l-oxa-l,13,15,18-tetraazapentacyclo [10.8.0.02,10.03,8.014,19]icosa- 3(8),4,6,12,14,16,18-heptaene (680 mg; 1.5 mmol; 65%; yellow solid)P25-212-PRI-US01Activity:POLQ polymerase assay - determination of POLQ inhibition (IC50 POLQ):The IC50 values were determined by a biochemical POLQ polymerase assay. DNA polymerase theta (POLQ) repairs DNA double-strand breaks (DSBs) with the polymerase activity of POLQ extending DNA strands in 5’ to 3’ direction. Elongation of DNA is initiated from an overlapping micro-homology region (4-6bp).Furthermore, processivity of POLQ is dependent on a 5 ’-phosphate of the downstream DNA strand. Elongation of the 3’ ends leads to gap filling. A DNA oligonucleotide template that mimics the natural substrate was used in the assay reaction. A mixture of POLQ protein and the test substance were incubated at different concentrations with addition of the DNA oligonucleotide template. POLQ activity was assessed by elongation of template and subsequent detection of the single stranded region within the template by a ROX-labelled short Oligonucleotide (7bp) probe. Probe binding and addition of the nucleic acid stain SYBR Green is creating an iFRET signal upon excitation. The SYBR Green signal is affected by the amount of doubled stranded DNA. The ratio between SYBR Green signal and ROX signal is used as read out. An increase in the signal ratio is caused by POLQ promoted strand extension and is proportional to the amount of product.In detail: The enzymatic POLQ assay was carried out as iFRET based 384-well assay. Purified human recombinant POLQ polymerase domain (human POLQ fragment, amino acids 1793-2590, UniProt ID 075417, expressed in insect cells) pre-incubated with DNA oligonucleotide template (generated by annealing of oligo 1:5'-CCACTGACTGTACGATGAAGATGCTGACGAGCTC-3', and oligo 2: 5'-phosphate-TACAGTCAGTGG-3' (metabion international AG)) was incubated in assay buffer for 15 minutes with the POLQ inhibitor in various concentrations and without test substance as negative or neutral control. The assay buffer comprised 20 mM TRIS-HCL pH 7.5, 8 mM MgCl2, 4.0% Glycerol, 0.5 mM DTT, 0.01% BSA, 0.01% Triton X-100. The test-substance solutions were dispensed into the microtitre plates using an ECHO 555 (Labcyte). Reactions were initiated by the addition of dNTP mix in assay buffer. The pharmacologically relevant assay volume was 5 pl. The final concentrations in the assay during incubation of the reaction mixture were 2.25 nM POLQ fragment, 68 nM DNA oligonucleotide template, and 10 pM dNTPP25-212-PRI-US01Mix (2.5 pM for each dNTP). After 30 min at room temperature, reactions were stopped by the addition of 3 pl of staining / stop solution containing ROX-labelled probe(oligo 3: 5’-Rox-GT(AP-dC)AG(AP-dC)A, metabion international AG) and SYBR Green (80 mM EDTA, 10 mM TRIS-HC1 pH 7.5, 0.005% Brij-35, 780nM ROX-labelled probe, 13.3x SYBR Green). After 15 min RT incubation for signal development, the plates were analysed in a plate reader (PheraStar FSX, BMG LabTech) measuring fluorescence at 520 nm following excitation at 485 nm. After excitation of SYBR Green as the donor at a wavelength of 485 nm, the emitted fluorescence light both of the acceptor ROX at 610 nm and also of the donor SYBR Green at 530 nm is measured. The amount of product generated is directly proportional to the quotient of the amounts of light emitted, i.e. the relative fluorescence units (RFU) at 530 nm and 610 nm. The measurement data were processed by means of the Genedata Screener software. In particular, ICso values were determined by fitting a dose-response curve to the data points using nonlinear regression analysis.ICso = half-maximum inhibitory concentrationbp = base pairiFRET = induced fluorescence resonance energy transferTRIS-HCl = Tris(hydroxymethyl)aminomethane HydrochlorideMgCl2= magnesium chlorideDTT = dithiothreitolBSA = Bovine Serum AlbumindNTP = DeoxynucleotideEDTA = ethylenediamine tetraacetateRT = room temperatureP25-212-PRI-US01P25-212-PRI-US01IC50 (nM)+++ 1-99 nM++ 100-499 nM+ 500-999 nMGreater than 1000 nM

Claims

1. P25-212-PRI-US01CLAIMSWhat is claimed:

1. A compound of Formula I or II or pharmaceutically acceptable salt thereof,wherein:R1is independently selected for each occurrence from the group consisting of C1-C6 alkyl, C1-C6haloalkyl, -O-C1-C6 alkyl and hydrogen;X is N or CR2;R2is selected from the group consisting of halogen, C1-C6 alkyl, C1-C6haloalkyl, -O-C1-C6 alkyl and hydrogen;A is selected from the group consisting of optionally substituted aromatic, optionally substituted heteroaromatic, optionally substituted C3-C8 cycloalkyl and optionally substituted C2-C8 heteroalkyl.

2. The compound according to claim 1 wherein A is selected from the group consisting ofP25-212-PRI-US01R3is selected independently for each occurrence from the group consisting of hydrogen, halogen, C1-C8alkyl, C1-C6 haloalkyl, -NR4R5,R4and R5are each independently selected from the group consisting of hydrogen, Ci-R6is selected from the group consisting of C1-C6 haloalkyl, C1-C8alkyl and Ci-Cs alkenyl;R7is selected from hydrogen and C1-C8alkyl;R8is independently selected from the group consisting of hydrogen, C1-C6 alkyl andR9is selected from the group consisting of C1-C6 haloalkyl, C1-C8alkyl and Ci-Cs alkenyl;R10and R11are each independently selected from hydrogen and C1-C6 alkyl or maybe taken together to form a 3-8 member carbocyclic ring optionally interrupted by 1-3 heteroatoms chosen from -O- and -NR12-;P25-212-PRI-US01R12is selected from hydrogen and C1-C6 alkyl;n is selected from 0, 1, 2 and 3;o is selected from 0, 1, 2 and 3;p is selected from 1, 2, 3 and 4;3. The compound according to claim 1 wherein R1is selected independently for each occurrence from the group consisting of hydrogen and halogen.

4. The compound according to claim 3 wherein R1is selected independently for each occurrence from the group consisting of -F and hydrogen.

5. The compound according to claim 1 wherein X is N.

6. The compound according to claim 1 wherein X is CR2.

7. The compound according to claim 6 wherein R2is selected from the group consisting of hydrogen and halogen.

8. The compound according to claim 7 wherein R2is hydrogen.

9. The compound according to claim 7 wherein R2is -F.

10. The compound according to claim 1 wherein A is11. The compound according to claim 10 wherein R3is independently selected for each occurrence from the group consisting of hydrogen, -CH3 and -NR4R5wherein R4and R5are each independently selected from the group consisting of hydrogen, Ci-and R6is selected from the group consisting of C1-C6 haloalkyl, C1-C8alkyl and Ci-Cs alkenyl.P25-212-PRI-US0112. The compound according to claim 11 wherein -NR4R5is selected from the group consisting ofwherein R13and R14are independently selected from hydrogen, halogen and C1-C2 alkyl.

13. The compound according to claim 12 wherein R13is -CH3 and R14is -Cl.

14. The compound according to claim 12 wherein R13is -F and R14is -Cl.

15. The compound according to claim 10 wherein R3is selected from the group consisting of hydrogen, -CH3,P25-212-PRI-US01and R9is selected from the group consisting of C1-C6 haloalkyl, C1-C8alkyl and Ci-Cs alkenyl.

16. The compound according to claim 15 wherein R8is selected fromwhereinR15is a halogen or C1-C2 alkyl.

17. The compound according to claim 16 wherein R15is chloro.

18. The compound according to claim 1 wherein A is selected from the group consisting ofindependently selected for each occurrence from the group consisting of hydrogen, halogen, C1-C8alkyl and C1-C6 haloalkyl; and R4is hydrogen or -CH3.

19. The compound according to claim 18 wherein R3is selected from the group consisting of hydrogen, -CF3 and -CH3.

20. The compound according to claim 18 wherein A is selected from the group consisting of21. A compound or a pharmaceutically acceptable salt thereof selected from the group consisting ofP25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US01P25-212-PRI-US0122. A method of treating cancer which comprises administering to a patient in need thereof, a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to claims 1 or 21.

23. A method according to claim 22 wherein the cancer is a solid cancer.P25-212-PRI-US0124. A method according to claim 22 wherein the cancer is breast, ovarian, pancreatic or prostate.

25. A method according to claim 22 wherein the cancer comprises a BRCA1 and / or BRCA2 mutation.